| Entries |
| Document | Title | Date |
|---|
| 20080219980 | Bi-Specific Complexes for Targeting Cells Involved in Allergic-Type Reactions, Compositions and Uses Thereof - Disclosed are bi-specific complexes aimed at inhibiting mast cells, eosinophils and/or basophils, and thus, at inhibiting allergy-type reactions. In particular, said complexes are best exemplified by bi-specific antibodies, which bind to two targets present in the same cell. One target is the inhibitory receptor IRp60. The second target is a cell-specific activator, e.g. IgE, cKIT, FcεRI, IL5R or CCR3. Binding of the bi-specific antibody to its targets results in the induction of an inhibitory pathway, through the inhibition of the signaling from the activator. Compositions and uses of the bi-specific complexes are also described. | 09-11-2008 |
| 20080241141 | METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER - Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis. | 10-02-2008 |
| 20080241142 | Neuropilin/VEGF-C/VEGFR-3 Materials and Methods - The present invention relates to identifying modulators of VEGF-C or VEGF-D ligand binding to the nervous system transmembrane protein neuropilin-2 and materials and methods for detecting said modulators. | 10-02-2008 |
| 20080299120 | MULTIVALENT ANTIBODIES AND USES THEREFOR - The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies. | 12-04-2008 |
| 20080299121 | Multivalent recombinant antibodies for treating HRV infections - The present invention relates to high affinity multivalent recombinant antibodies and multivalent peptides against ICAM-1 and/or LDL receptor and pharmaceutical compositions containing such multivalent antibodies or multivalent peptides. The present invention also relates to methods of using such multivalent antibodies or multivalent peptides to prevent and treat human rhinovirus infection and diseases and pathological conditions associated therewith. | 12-04-2008 |
| 20080305105 | BISPECIFIC ANTIBODIES - The present invention discloses bispecific antibodies comprising two antibody variable domains on a single polypeptide chain, wherein a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen on the human immune effector cell, the first portion consisting of one antibody variable domain, and a second portion of the bispecific antibody specifically binding to a target antigen other than the effector antigen, the target antigen on a target cell other than the human immune effector cell, the second portion comprising one antibody variable domain. | 12-11-2008 |
| 20080317751 | Idiotype Vaccination with Bispecific and Multispecific Immunoglobulin Molecules - The present application relates to immunoglobulin polypeptides comprising at least two immunoglobulin complementarity determining regions, one that binds to an immune receptor and the other which comprises an idiotype to which an immune response is desired. | 12-25-2008 |
| 20090004192 | Recombinant anti-epidermal growth factor receptor antibody compositions - The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody. | 01-01-2009 |
| 20090028859 | Bispecific antibodies that bind to vegf receptors - The present invention is directed to production of antigen-binding proteins that bind specifically to an extracellular domains of two different VEGF receptors. The bispecific antigen-binding proteins block activation of the VEGF receptors and are used to reduce or inhibit VEGF-induced cellular functions such as mitogenesis of vascular endothelial cells and migration of leukemia cells. The antigen-binding proteins of the present invention can be monovalent or multivalent, have antigen-binding sites consisting of immunoglobulin heavy chain and light chain variable domains and may further include immunoglobulin constant domains. | 01-29-2009 |
| 20090028860 | Use of IL-17 Expression to Predict Skin Inflammation; Methods of Treatment - Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17 and/or IL-23. | 01-29-2009 |
| 20090053225 | Recombinant antibodies against cd55 and cd59 and uses thereof - The present invention relates to recombinant antibody molecules and functional fragments thereof, useful for neutralizing the complement regulatory proteins CD55 and CD59, compositions comprising the recombinant molecules and methods of using the recombinant molecules for controlling complement resistance in cancer. The present invention further relates to heterodimeric diabody molecules comprising variable regions specific for CD55/CD59 and CD20. | 02-26-2009 |
| 20090074770 | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof - The present invention relates to amino acid sequences that binding to serum proteins such as serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides, is essentially independent in the pH range 5 to 8. | 03-19-2009 |
| 20090074771 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention. | 03-19-2009 |
| 20090074772 | Anti-CD70 Antibody and Its Use for the Treatment of Cancer and Immune Disorders - Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent. | 03-19-2009 |
| 20090092610 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention. | 04-09-2009 |
| 20090092611 | ANTIBODIES THAT BIND BOTH BCMA AND TACI - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor, and the B-cell maturation (BCMA) receptor. | 04-09-2009 |
| 20090098124 | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT HEAVY CHAINS AND METHODS OF USING SAME - The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant heavy chain, which variant heavy chain comprises constant domains from more than one IgG isotype. The variant heavy chain of the invention may further comprise at least one amino acid modification relative to the parental heavy chain, such that the Fc region of said variant heavy chain binds an FcγR with an altered affinity relative to a comparable molecule comprising the wild-type heavy cahin. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC. | 04-16-2009 |
| 20090104194 | BI-DIRECTIONAL ANTIBODY FOR TREATMENT OF OCULAR DISORDERS - A system and method for treating ocular disorders are disclosed. Specifically, the system and method administer bi-directional antibodies to treat a retina. Structurally, each bi-directional antibody has a first receptor arm and a second receptor arm. Further, each first receptor arm possesses binding affinity for retinal cells and each second receptor arm possesses binding affinity for melanin. After the antibodies are administered to the retina, the first receptor arms attach to the retinal cells. Thereafter, melanin is delivered to the retina and the second receptor arms are fixed to the melanin. In this manner, melanin is concentrated at the retinal cells. | 04-23-2009 |
| 20090104195 | TARGETED LIGANDS - The invention contemplates a composition containing a multispecific ligand containing at least a first ligand binding moiety and a second ligand binding moiety. The first ligand binding moiety specifically binds with a pre-selected first affinity to at least a first ligand. The first ligand has a first biodistribution. The second ligand binding moiety specifically binds with a pre-selected affinity to at least a second ligand. The second ligand has a second biodistribution. The affinity of first and second ligand binding moieties are selected to bias the biodistribution of the multispecific ligand in favor of a selected location of one or both of the ligands. | 04-23-2009 |
| 20090117112 | IMMUNOMODULATORY COMPOSITIONS AND USES THEREFOR - The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on the host cells results in suppression of the immune response. The present invention provides agents such as antibodies, and antigen-binding fragments thereof, small molecules, aptamers, small interfering RNAs, and peptide-IgFc fusion polypeptides that interact with one or more of LAR, RPTP-δ, and RPTP-σ expressed by immune cells or interact with a polynucleotide encoding the RPTP. Also provided are RPTP Ig domain oligomers and Fc fusion polypeptides. Such agents are useful for treating an immunological disorder in a subject according to the methods described herein. | 05-07-2009 |
| 20090130105 | COMPOSITIONS THAT BIND MULTIPLE EPITOPES OF IGF-1R - The instant invention is based, at least in part on the finding that binding molecules which bind to different epitopes within IGF-1R result in improved IGF-1 and/or IGF-2 blocking capabilities when compared to binding molecules that bind to a single IGF-1R epitope. The instant invention provides compositions that bind to multiple epitopes of IGF-1R, for example, combinations of monospecific binding molecules or multispecific binding molecules (e.g., bispecific molecules). Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize IGF-1R signaling are also provided. | 05-21-2009 |
| 20090142343 | Anti-VEGF antibodies - The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies. | 06-04-2009 |
| 20090155275 | MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF - The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases. | 06-18-2009 |
| 20090162356 | CRIg antagonists - The present invention concerns blocking antibodies specifically binding a recently discovered macrophage specific receptor, CRIg, and their use to prevent cellular entry of intracellular pathogens, such as viruses, bacteria or parasites as well as for prevention of unwanted clearance of erythrocytes and platelets. | 06-25-2009 |
| 20090162357 | Diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases - Complement is recognized as an important, humoral defense system involved in the innate (nonspecific) recognition and elimination of microbial invaders, other foreign particles or molecules, and antigen-antibody complexes from the body. The present invention makes use of the surprising notion that the handling of lipids by the body, rather than its antimicrobial activity, is the primary and most ancient function of the complement system. Consequently, atherosclerosis as observed in disorders associated with disturbed lipid metabolism (familial combined hyperlipidemia (FCHL), postprandial hyperlipidemia, hypertriglyceridemia with low levels of HDL cholesterol, and insulin resistance associated with type-II diabetes and obesity), is ascribed to either genetic or acquired defects in ancient (activatory and/or regulatory) complement components. Based on this new insight, novel preventive measures and treatment modalities of disturbed lipid metabolism are introduced. | 06-25-2009 |
| 20090162358 | ANTIGEN BINDING PROTEINS - Antigen binding proteins that bind β-amyloid peptide, in particular human β-amyloid peptide; methods of treating diseases or disorders characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterised by elevated β-amyloid levels or β-amyloid deposits, including age related macular degeneration and glaucoma type diseases and β-amyloid dependent cataract formation, with said antigen binding proteins; pharmaceutical compositions comprising said antigen binding proteins; and methods of manufacture. | 06-25-2009 |
| 20090162359 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 06-25-2009 |
| 20090162360 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 06-25-2009 |
| 20090169552 | NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5 - The present invention relates to methods of treating immune disorders and cancers. In particular the invention provides methods of inhibiting the negative immunomodulatory effects of ERp-5 on T cells and dendritic cells, in conjunction with other surface receptors. | 07-02-2009 |
| 20090191201 | Combination of the application of antibodies for immunostimulation together with glucocorticoids - The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid. | 07-30-2009 |
| 20090191202 | Methods for manipulating phagocytosis mediated by CD47 - Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable. | 07-30-2009 |
| 20090208504 | Polypeptides involved in immune response - Novel polypeptides which comprise a receptor-ligand pair involved in T-cell, activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders. | 08-20-2009 |
| 20090214540 | Protein involved in cancer - The present invention relates to new uses of PSK-1 in the diagnosis, screening, treatment and prophylaxis of ovarian and lung cancer. The invention also provides compositions comprising PSK-1, including vaccines, antibodies that are immunospecific for PSK-1 and agents which interact with or modulate the expression or activity of PSK-1 or which modulate the expression of the nucleic acid which codes for PSK-1. | 08-27-2009 |
| 20090214541 | Combination Therapy Using Anti-EGFR and Anti-HER2 Antibodies - The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer. | 08-27-2009 |
| 20090232811 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 09-17-2009 |
| 20090232812 | MUC1 EXTRACELLULAR DOMAIN AND CANCER TREATMENT COMPOSITIONS AND METHODS DERIVED THEREFROM - The present invention provides compositions and methods for inhibiting the proliferation of cancer cells and for the treatment of tumors with antagonists of the binding of ligands to the extracellular domain of MUC1, such binding being related to an oncogenic function of MUC1. | 09-17-2009 |
| 20090252731 | Multivalent Carriers of Bi-Specific Antibodies - Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods. | 10-08-2009 |
| 20090258019 | Diagnosis of carcinoma using RAIG1 polypeptides - The present invention relates to the new uses of a polypeptide (retinoic acid-inducible gene 1; RAIG1, also known as hypothetical protein FLJ10899 or retinoic acid induced 3) compositions comprising the polypeptide, including vaccines, antibodies that are immunospecific for the polypeptide and agents which interact with or modulate the expression or activity of the polypeptide or the expression of the nucleic acid which encodes the polypeptide. The use of the polypeptide in the diagnosis, screening and treatment of carcinoma, e.g. breast cancer, pancreatic cancer, lung cancer, liver cancer, ovarian cancer, colon cancer and/or osteosarcoma, is also provided. | 10-15-2009 |
| 20090263392 | METHODS OF MODIFYING ANTIBODIES FOR PURIFICATION OF BISPECIFIC ANTIBODIES - The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of two types of antibodies that constitute a bispecific antibody. Furthermore, the inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column by linking respective antigen binding sites (heavy chain variable regions) to the antibody constant regions having different isoelectric points, and then coexpressing these antibodies. | 10-22-2009 |
| 20090291081 | Dual-specific IL-1A/IL-1b antibodies - The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-1α and human IL-1β. The dual specific antibodies of the invention also neutralize both human IL-1α and human IL-1β. The invention also provides domain antibodies (dAbs) specific for human IL-1α and human IL-1β. | 11-26-2009 |
| 20100003254 | Antibody Substituting for Function of Blood Coagulation Factor VIII - The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII. | 01-07-2010 |
| 20100015146 | TREATING DIABETES USING INHIBITORS OF IL-1 - The present invention describes a method of treating diabetes or metabolic syndrome with a compound that inhibits (a) IL-1, (b) the synthesis of IL-1, or (c) the release of IL-1. | 01-21-2010 |
| 20100055103 | CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES - The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses. | 03-04-2010 |
| 20100074900 | PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 03-25-2010 |
| 20100111954 | USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE - Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity. | 05-06-2010 |
| 20100129368 | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof - The present invention relates to amino acid sequences that binding to serum proteins such as serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides, is essentially independent in the pH range 5 to 8. | 05-27-2010 |
| 20100136009 | OVR110 Antibody Compositions and Methods of Use - Isolated antibodies and antigen binding fragments thereof directed against Ovrl 10 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovrl 10-expressing cancer cells and alleviating or treating an Ovrl 10-expressing cancer in a mammal. The anti-Ovrl 10 antibodies modulate Ovrl 10 function or internalize upon binding to Ovrl 10 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovrl 10 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovrl 10 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided. | 06-03-2010 |
| 20100158914 | KLOTHO BETA - The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. | 06-24-2010 |
| 20100183615 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS - The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. | 07-22-2010 |
| 20100196376 | METHOD FOR REDUCING ALLERGEN-INDUCED AIRWAY HYPERRESPONSIVENESS - Disclosed is a method to reduce airway hyperresponsiveness, such as allergen-induced airway hyperresponsiveness, in a mammal by administering an agent that increases the biological activity of a CGRP receptor. Also disclosed are methods for identifying compounds useful in the present method. | 08-05-2010 |
| 20100226923 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-09-2010 |
| 20100233173 | MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF - The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases. | 09-16-2010 |
| 20100239582 | Dual Specificity Antibody Fusions - The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest. | 09-23-2010 |
| 20100239583 | ANTIBODIES AGAINST FLAGELLIN AND USES THEREOF - The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, | 09-23-2010 |
| 20100247539 | Antibodies that Inhibit Transport Activity of Peptide Transporters - The present inventors discovered that the PepT-binding antibodies have the ability to inhibit the transport activity of peptide transporters, as a result of dedicated research. These antibodies may be utilized as cell growth inhibitors, for example, for treating and preventing cancer. | 09-30-2010 |
| 20100254986 | METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES - The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. “Protuberances” are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis. | 10-07-2010 |
| 20100254987 | ENGINEERED PROTEINS WITH HIGH AFFINITY FOR DOTA CHELATES - The present invention features, inter alia, compositions and methods for the treatment of cancer and infectious disease. The compositions include engineered proteins that specifically bind a metal chelate and may be bispecific. For example, the engineered proteins may bind (a) a target (e.g., a cellular protein) on a cancerous cell or a pathogen and (b) a metal chelate comprising DOTA, or an active variant thereof, and a metal ion such as a radionuclide. By virtue of the multiple binding sites, the engineered protein effectively delivers a metal chelate to a cell one wishes to destroy. | 10-07-2010 |
| 20100254988 | Bispecific Anti ErbB2 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-2 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 10-07-2010 |
| 20100254989 | Bispecific Anti ErbB1 / Anti c Met Antibodies - The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 10-07-2010 |
| 20100254990 | ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS - The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorder in a patient without having a significant adverse effect on the immune system of the patient. | 10-07-2010 |
| 20100254991 | Use of Cytokine Expression to Predict Skin Inflammation; Methods of Treatment - Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23. | 10-07-2010 |
| 20100266595 | TREATMENT OF INSULIN-RESISTANT DISORDERS - The invention concerns the treatment of insulin-resistant disorders. In particular, the invention concerns the treatment of insulin-resistant disorders by administration of IL-17, such as IL-17A and/or IL-17F antagonists, such as anti-IL-17A and/or IL-17F and/or IL-17Rc antibodies, or antibody fragments. | 10-21-2010 |
| 20100278829 | DUAL INHIBITION OF IMMUNOPHILIN/CYCLOPHILIN FAMILY MEMBERS AND EMMPRIN IMMUNOGLOBULIN RECEPTOR SUPERFAMILY MEMBERS - The present disclosure provides methods and compositions for modulating an adaptive immune response without significantly affecting an innate immunity response in a subject by modulating a combination of an Immunophilin/Cyclophilin Family Member and an EMMPRIN Immunoglobulin Receptor Superfamily Member. The present invention also provides methods and compositions for treating a variety of clinical conditions by modulating an Immunophilin/Cyclophilin Family Member and an EMMPRIN Immunoglobulin Receptor Superfamily Member. | 11-04-2010 |
| 20100297127 | USE OF IL-27 ANTAGONISTS TO TREAT LUPUS - This invention relates to methods of treating the autoimmune disorder lupus with IL-27 antagonists, as well as articles of manufacture comprising IL-27 antagonists. The invention also relates to methods and kits for identifying patients that are likely to respond to an IL-27 antagonist treatment. | 11-25-2010 |
| 20100303816 | ANTIBODIES AGAINST HUMAN MELANOMA-ASSOCIATED CHONDROITIN SULPHATE PROTEOGLYCAN (MCSP) - The present invention provides isolated antibodies (e.g., humanized or human antibodies) that bind to the membrane-proximal domain (MP) of human Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), and are capable of mediating cytolysis of a cell expressing MCSP in the presence of human effector cells or complement. Methods of using such antibodies to induce cytolysis (e.g., ADCC or CDCC) of cells expressing MP-MCSP are also provided. | 12-02-2010 |
| 20100310564 | Method for the Treatment of Glomerulonephritis - The present invention provides a method for the treatment and/or prophylaxis of glomerulonephritis associated with one or more disorders selected from the group consisting of Goodpasture's syndrome, a vasculitic disorder, Wegener's disease, IgA nephropathy and an inflammatory disease with basement membrane involvement comprising administering a therapeutically effective amount of agent which interacts with or modulates the expression or activity of a mammalian IL-6 polypeptide. | 12-09-2010 |
| 20100310565 | ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME - The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation. | 12-09-2010 |
| 20100316645 | Bispecific Antigen Binding Proteins - The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-16-2010 |
| 20100322933 | INTRAOPERATIVE TRIFUNCTIONAL ANTIBODY APPLICATION FOR PROPHYLAXIS OF INTRAPERITONEAL TUMOR CELL DISSEMINATION - The invention describes the use of trifunctional bispecific and trispecific antibodies for destroying tumor cells which e.g. are disseminated intraperitoneally due to a surgical intervention, wherein the antibody is administered intraoperatively, preferably directly locally into the abdominal cavity. | 12-23-2010 |
| 20100322934 | Bispecific, Tetravalent Antigen Binding Proteins - The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-23-2010 |
| 20100322935 | Tri- or Tetraspecific Antibodies - The present invention relates to tri- or tetraspecific antibodies, their manufacture and use. | 12-23-2010 |
| 20110002929 | AMINO ACID SEQUENCES DIRECTED AGAINST RANK-L AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF BONE DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 01-06-2011 |
| 20110002930 | Activated T Cells - Provided are compositions comprising activated T cells and activated T cells armed with bispecific antibodies directed at cancer antigens which are poor responders to alloantigen, and methods of using the compositions to help engraftment and improve anti-tumor effects. | 01-06-2011 |
| 20110002931 | BISPECIFIC ANTIBODIES THAT BIND TO COMPLEMENT PROTEINS - The present disclosure relates to bispecific antibodies that can bind to two or more different epitopes. For example, the bispecific antibodies described herein can bind to two or more different proteins, wherein at least two of the proteins are selected from C5a, C5b, a cellular receptor for C5a (e.g., C5aR1 or C5L2), the C5b-9 complex, and a component or intermediate of terminal complement such as C5b-6, C5b-7, or C5b-8. The bispecific antibodies described herein are useful for, e.g., inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 complex) and/or C5a anaphylatoxin-mediated inflammation (e.g., C5a-mediated chemotaxis of inflammatory immune cells). Accordingly, the bispecific antibodies can be used in methods for treating a variety of complement pathway-associated disorders. | 01-06-2011 |
| 20110008345 | ANTIGEN-BINDING CONSTRUCTS - The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 01-13-2011 |
| 20110008346 | BIOMARKERS FOR CARDIOVASCULAR DISEASE - The present invention relates to a method of diagnosis or prognosis of cardiovascular disease in a subject, said method comprising the steps of detecting the presence of activated endothelial progenitor cells (EPCs) in a sample of a circulation fluid of said subject. The invention further relates to biomarkers for diagnosis or prognosis of cardiovascular disease in a patient, said biomarker comprising the expression product of a gene the expression of which is regulated during vasculogenesis. | 01-13-2011 |
| 20110014198 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 01-20-2011 |
| 20110020346 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 01-27-2011 |
| 20110033465 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS - The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9. | 02-10-2011 |
| 20110038871 | CCR2 INHIBITORS FOR TREATING CONDITIONS OF THE EYE - Disclosed herein are compositions and methods for treating conditions of the eye using CCR2. | 02-17-2011 |
| 20110059088 | Protein involved in ovarian cancer - The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCP1 and agents which interact with or modulate the expression or activity of CDCP1 or which modulate the expression of the nucleic acid which codes for CDCP1. | 03-10-2011 |
| 20110059089 | Protein Markers for Cardiovascular Events - The present invention relates to a method for predicting the risk of a subject developing a cardiovascular event comprising detecting at least one biomarker in (a sample of) the cardiovascular system from said subject, wherein said biomarker comprises at least one protein selected from the group consisting of Tumor Necrosis Factor Alpha Precursor; Lysosomal-associated Membrane Protein (1); Interleukin-5 Precursor; Interleukin-6 Precursor; C-C Motif Chemokine (2) Precursor; C-C Motif Chemokine (5) Precursor RANTES; Cathepsin L1 Precursor; Adenylate Kinase (1); Leukotriene B4 Receptor (1); Complement Factor D; Secreted Phosphoprotein (1); Small Inducible Cytokine A17 Precursor; C-X-C Motif Chemokine (10) Precursor; Tumor Necrosis Factor Ligand Superfamily Member (11) (RANKL); C-C Motif Chemokine (18) Precursor; 72 kDa Type IVCollagenase Precursor; Neutrophil Collagenase Precursor; fatty acid binding protein (4); calpain (2), (m/II) large subunit; Macrophage Migration Inhibitory Factor; Cathepsin S Precursor; Interleukin (13) Precursor; and soluble ICAM-1. | 03-10-2011 |
| 20110076275 | Method of Modifying Isoelectric Point of Antibody Via Amino Acid Substitution in CDR - The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions. | 03-31-2011 |
| 20110086032 | ANTI-FGF19 ANTIBODIES AND METHODS USING SAME - The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4. | 04-14-2011 |
| 20110091463 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 04-21-2011 |
| 20110097327 | PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS ASSOCIATED WITH RECEPTOR-DESENSITIZATION - Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods. | 04-28-2011 |
| 20110123532 | Method for Making Heteromultimeric Molecules - The present invention provides methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising said molecules. The method includes introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered. | 05-26-2011 |
| 20110123533 | Using EGFRvIII to Identify and Target Cancer Stem Cells - A set of markers for cancer stem cells are provided. The cells can be prospectively isolated or identified from primary tumor samples, and possess the unique properties of cancer stem cells in functional assays for tumor initiation, cancer stem cell self-renewal and differentiation. In addition, cancer stem cells can be used as a predictor for disease progression. The CSC have the phenotype of being positive for expression of CD133, and for EGFRvIII. In another embodiment of the invention, compositions are provided of a bispecific reagent that recognizes CD133 and EGFRvIII, including bispecific antibodies, which are optionally conjugated to a detectable marker, chemotherapeutic agent are radionuclide for imaging or therapy. | 05-26-2011 |
| 20110123534 | NOVEL COMPOUNDS FOR MODULATING NEOVASCULARISATION AND METHODS OF TREATMENT USING THESE COMPOUNDS - The invention relates to a method for modulating neovascularisation comprising administering to a subject one or more compound selected from an isolated nucleic acid molecule comprising a gene selected from the group consisting of RIKEN cDNA 9430020K01, Agtrl1, Apelin, Stabilin 1, Stabilin 2, TNFaip8l1, TNFaip8 and FGD5, and homologues thereof; a gene product encoded by said genes or their homologues genes, and functional fragments thereof; an antibody or derivative thereof directed against a gene product of said genes or their homologues genes, and functional fragments thereof; an antisense molecule capable of binding to a gene or an mRNA gene product of said genes and homologues thereof; a small molecule interfering with a biological activity of a gene product of said genes and homologues thereof, and a (glyco)protein, a hormone and other biologically active compounds capable of interacting with said genes and homologues thereof or with a gene product thereof. | 05-26-2011 |
| 20110142840 | Compositions and Methods for Diagnosing and Treating Cancer - Isolated antibodies that specifically bind the human MET Receptor and inhibit MET signaling are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of the provided MET antibodies and combinations thereof. | 06-16-2011 |
| 20110150877 | EPHRIN-B RECEPTOR PROTEIN INVOLVED IN CARCINOMA - The present invention provides a polypeptide (CCMP-1) of use in the diagnosis, screening, treatment and prophylaxis of carcinoma. Also provided are compositions comprising the protein, vaccines and antibodies that are immunospecific for the protein. | 06-23-2011 |
| 20110150878 | COMPOSITIONS AND METHODS FOR MANIPULATING LEVELS OF ANTIGEN-SPECIFIC ANTIBODIES IN A MAMMAL - The invention provides compositions and methods for increasing the levels of an autoantigen-specific IgM antibody in a mammal and, thus, decreasing the levels of a circulating autoantigen in a mammal. Using these autoantigen-specific IgM antibodies, the invention provides compositions and methods for ameliorating an autoimmune disease in a mammal. In one aspect, the invention provides compositions and methods for increasing the levels of an antigen-specific IgG antibody in a mammal and, thus, decreasing the levels of a circulating antigen in a mammal. Using these antigen-specific IgG antibodies, the invention provides compositions and methods for ameliorating a disease or condition in a mammal, e.g., a cancer or a foreign antigen, such as a pathogen. | 06-23-2011 |
| 20110165162 | Methods for Treating Cancers Comprising K-ras Mutations - Methods of inhibiting tumor growth, methods of treating cancer, and methods of reducing the frequency of cancer stem cells in a tumor are described. Particularly, the methods are directed to tumors or cancers that comprise a K-ras mutation. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described. | 07-07-2011 |
| 20110177073 | Recombinant production of mixtures of antibodies - Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields. | 07-21-2011 |
| 20110177074 | COMPOSITIONS AND METHODS FOR INHIBITING PDGFRBETA AND VEGF-A - Disclosed are antagonists of PDGF receptor β (PDGFRβ) and VEGF-A, including neutralizing anti-PDGFRβ and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFRβ and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFRβ and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFRβ and/or VEGF-A antagonist. | 07-21-2011 |
| 20110177075 | TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 07-21-2011 |
| 20110189184 | MODULATION OF NEURAL STEM CELLS AND NEURAL PROGENITOR CELLS - The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells via S1P or LPA signaling. These methods are useful for reducing at least one symptom of the disorder. | 08-04-2011 |
| 20110200602 | ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE - The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies. | 08-18-2011 |
| 20110206672 | Antigen-Binding Molecule And Uses Thereof - In one aspect, the present invention relates to an antigen-binding molecule specific for albumin and CD3 which may comprise two polypeptide chains, each polypeptide chain having at least four variable domains in an orientation preventing Fv formation and the two polypeptide chains are dimerized with one another thereby forming a multivalent antigen-binding molecule. On each of the two polypeptide chains the four variable domains may be arranged in the order V | 08-25-2011 |
| 20110212094 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 09-01-2011 |
| 20110223167 | COMBINATION THERAPY USING RECEPTOR TYROSINE KINASE INHIBITORS AND ANGIOGENESIS INHIBITORS - The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of receptor tyrosine kinase antagonists/inhibitors, especially ErbB receptor antagonists, more preferably EGF receptor (Her 1) antagonists and anti-angiogenic agents, preferably integrin antagonists, optionally together with agents or therapy forms that have additive or synergistic efficacy when administered together with the combination of antagonists/inhibitors, such as chemotherapeutic agents and or radiation therapy. The therapy can result in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone. | 09-15-2011 |
| 20110223168 | LIGAND THAT HAS BINDING SPECIFICITY FOR IL-4 AND/OR IL-13 - The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity. | 09-15-2011 |
| 20110223169 | IL-17 ANTIBODY INHIBITOR FOR TREATING DRY EYE - Disclosed herein is a method of treating dry eye with an IL-17 antibody. | 09-15-2011 |
| 20110223170 | KLK-13 ANTIBODY INHIBITOR FOR TREATING DRY EYE - Disclosed herein is a method of treating dry eye with a KLK-13 antibody. | 09-15-2011 |
| 20110229475 | NOVEL COMPOUNDS - The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to (cross react with) human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78. | 09-22-2011 |
| 20110229476 | MONOSPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD OF USE - This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases. | 09-22-2011 |
| 20110229477 | Methods for Treatment of HIV and Other Infections Using a T Cell or Viral Activator and Anti-Retroviral Combination Therapy - Disclosed is a method for treating infection with a pathogen. The method involves administration of (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD4+ T cells from peripheral blood mononuclear cells isolated from human subjects in the presence of an antiretroviral drug and for treating HIV infection by infusing the expanded CD4+ cells into HIV-infected patients. | 09-22-2011 |
| 20110236388 | BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 09-29-2011 |
| 20110250203 | ANTI-CD5 ANTIBODIES - The present invention relates to the field of compositions comprising anti-CD5 antibodies. In particular, the present invention concerns an antibody composition comprising at least two anti-CD5 antibodies capable of binding distinct CD5 epitopes. The invention further concerns bi-specific molecules having the binding specificities of said antibody compositions. The invention also relates topharmaceutical compositions, use of antibody compositions and methods for manufacturing antibody compositions. The invention further relates to cell banks and a method for killing cells. | 10-13-2011 |
| 20110256142 | NOVEL METHODS AND ANTIBODIES FOR TREATING CANCER - The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein—said first antibody binds EGFR, —said second antibody binds EGFR, —said first and second antibody are non-cross-blocking, and—the dosage regimen is such that CDC is obtained at the tumor site. | 10-20-2011 |
| 20110256143 | FDF03 Antibodies and uses thereof - The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer. | 10-20-2011 |
| 20110280878 | SUBSTANCE SPECIFIC TO HUMAN PD-1 - The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy. | 11-17-2011 |
| 20110287009 | Production of Heteromultimeric Proteins - Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies. | 11-24-2011 |
| 20110293613 | BISPECIFIC ANTIBODIES - The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-01-2011 |
| 20110318349 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 12-29-2011 |
| 20110318350 | ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation. | 12-29-2011 |
| 20120003225 | AUTOANTIBODIES IN THE DETECTION AND TREATMENT OF CANCER - Methods, kits, and compositions for detecting and/or treating cancer based on detecting and/or administering an antibody, which can optionally be a bispecific antibody, having the immunoreaction characteristics of a cancer-associated autoantibody; an antigen for a cancer-associated autoantibody; or both an antibody having the immunoreaction characteristics of a cancer-associated autoantibody and an antigen for a cancer-associated autoantibody, in or to a subject in need thereof. | 01-05-2012 |
| 20120014956 | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-ALPHA INHIBITOR - The invention provides methods of determining or predicting the responsiveness of a subject to treatment with a TNFα inhibitor, such as a TNFα antibody by determining genetic factors. | 01-19-2012 |
| 20120014957 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 01-19-2012 |
| 20120020971 | ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION - Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza. | 01-26-2012 |
| 20120070438 | Methods for Treating Melanoma - Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described. | 03-22-2012 |
| 20120070439 | ANTIGEN-BINDING PROTEINS - The invention relates to linkers suitable for use in antigen-binding proteins, certain antigen binding proteins and methods of making such proteins and uses thereof. | 03-22-2012 |
| 20120076786 | BISPECIFIC ANTIBODIES - The present invention provides compositions and methods for targeting stem cells to injured cardiac tissue. | 03-29-2012 |
| 20120076787 | COMBINATION OF A TNF-ALPHA ANTAGONIST AND A VEGF ANTAGONIST FOR USE IN THE TREATMENT OR PREVENTION OF DISEASES OF THE EYE - The invention relates to combinations of TNFα antagonists with VEGF antagonists for use in treating diseases of the eye, and provides antigen-binding proteins which bind to TNFα or a TNFα receptor and/or VEGF or a VEGF receptor. | 03-29-2012 |
| 20120121596 | BISPECIFIC ANTI-HER ANTIBODIES - The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists. | 05-17-2012 |
| 20120121597 | FUSION PROTEINS FOR HIV THERAPY - Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins. | 05-17-2012 |
| 20120121598 | COMPOSITIONS CONTAINING ANTIBODIES FOR TREATING CD5+HLA-DR+B OR T CELL RELATED DISEASES - The present invention relates to compositions containing antibodies for treating CD5+ HLA-DR+ B OR T cell related diseases such as B or T cell malignances (leukaemia and lymphoma), autoimmune diseases and T cell related diseases as transplantation and graft rejection. | 05-17-2012 |
| 20120121599 | COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY - This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits. | 05-17-2012 |
| 20120128675 | ANTI-FGF19 ANTIBODIES AND METHODS USING SAME - The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4. | 05-24-2012 |
| 20120156206 | C-MET ANTIBODY COMBINATIONS - The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein. | 06-21-2012 |
| 20120156207 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 06-21-2012 |
| 20120171209 | IMPROVED AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind (as defined herein) Interleukin-6 Receptor (IL-6R), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. In a specific aspect, the present invention provides amino acid sequences and polypeptides that are capable of binding to two or more different antigenic determinants, epitopes, parts, domains of IL-6R, also referred to as “multiparatopic” (such as e.g. “biparatopic” or “triparatopic”, etc.) amino acid sequences and polypeptides. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides, methods for preparing such amino acid sequences and polypeptides, host cells expressing or capable of expressing such amino acid sequences or polypeptides, compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 07-05-2012 |
| 20120177651 | ANTIGEN-BINDING PROTEINS - The invention relates to combinations of HGF antagonists with VEGF antagonists, and provides antigen-binding proteins which bind to HGF comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding protein has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 07-12-2012 |
| 20120177652 | BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY - Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agents are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided. | 07-12-2012 |
| 20120177653 | ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation. | 07-12-2012 |
| 20120183549 | CHEMOKINE RECEPTOR BINDING POLYPEPTIDES - The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2. | 07-19-2012 |
| 20120183550 | Therapeutic Using a Bispecific Antibody - Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules. | 07-19-2012 |
| 20120189630 | BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES - We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These are promising therapeutic agents. | 07-26-2012 |
| 20120189631 | PHARMACEUTICAL COMPOSITION FOR TREATING ISCHEMIC EVENTS - Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed. | 07-26-2012 |
| 20120195900 | TRI-VARIABLE DOMAIN BINDING PROTEINS AND USES THEREOF - The present invention provides engineered multivalent and multispecific binding proteins, as well as methods of making them. Methods for using the multivalent and multispecific binding proteins of the invention in the prevention, diagnosis, and/or treatment of disease are also provided. | 08-02-2012 |
| 20120195901 | Compositions and Methods for Binding Lysophosphatidic Acid - Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. | 08-02-2012 |
| 20120201823 | APRIL ANTAGONISTS AND METHODS OF USE - The present invention provides antagonists of APRIL. In particular, the APRIL antagonists block unique receptor binding sited on APRIL, BCMA. TACI, and/or HSPG. Also provided are methods of use. | 08-09-2012 |
| 20120213786 | Notch1 Binding Agents and Methods of Use Thereof - The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia. | 08-23-2012 |
| 20120213787 | STABLE ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS - The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient. | 08-23-2012 |
| 20120225071 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to nucleic acids which encode the heavy chains and light chains of a novel domain exchanged, bivalent, bispecific antibody, and vectors comprising the same. | 09-06-2012 |
| 20120225072 | STABLE FORMULATIONS OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND USES THEREOF - The present invention relates to stable formulations of polypeptides, e.g. immunoglobulin single variable domains. | 09-06-2012 |
| 20120225073 | Isolation and Use of Melanoma Cancer Stem Cells - A set of markers for melanoma cancer stem cells are provided. The cells can be prospectively isolated or identified from primary tumor samples, and possess the unique properties of cancer stem cells in functional assays for tumor initiation, cancer stem cell self-renewal and differentiation. In addition, cancer stem cells can be used as a predictor for disease progression. The CSC have the phenotype of being positive for expression CD271. | 09-06-2012 |
| 20120230999 | BISPECIFIC NANOBODIES AS A THERAPEUTIC FOR ALZHEIMER'S DISEASE - The present invention provides for the treatment of Alzheimer's disease. More specifically, a recombinant bispecific antibody fragment that simultaneously blocks beta-secretase activity while also promoting alpha-secretase activity, comprising a first portion and a second portion, wherein the first portion blocks beta secretase activity and the second portion promotes alpha-secretase activity. | 09-13-2012 |
| 20120237517 | Antibody Substituting for Function of Blood Coagulation Factor VIII - The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII. | 09-20-2012 |
| 20120244162 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS - The present invention relates to a polypeptide comprising a first human binding domain capbable of binding to an epitope of human and non-chimpanzee CD3ε (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acid sequences encoding the polypeptide, to vectors comprising the nucleic acid sequences and to host cells comprising the nucleic acid sequences or vectors containing the nucleic acid sequences. In another aspect, the invention provides for a pharmaceutical composition comprising the polypeptide and methods of medical treatment or use of the polypeptide. | 09-27-2012 |
| 20120244163 | BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF - Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways. | 09-27-2012 |
| 20120251541 | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation - The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins. | 10-04-2012 |
| 20120258108 | Dual Variable Domain Immunoglobulins and Uses Thereof - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 10-11-2012 |
| 20120258109 | ANTIBODIES THAT BIND TGF-ALPHA AND EPIREGULIN - The present invention provides antibodies that bind human TGF-alpha and human Epiregulin and are characterized as having high affinity, selective, and strong neutralizing properties. The antibodies are useful in the treatment of diabetic nephropathy. | 10-11-2012 |
| 20120258110 | FDF03 ANTIBODIES AND USES THEREOF - The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer. | 10-11-2012 |
| 20120263722 | Dual Variable Domain Immunoglobulins and Uses Thereof - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 10-18-2012 |
| 20120269812 | MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES - Provided herein are novel monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. Novel antiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided. | 10-25-2012 |
| 20120269813 | POLYCLONAL BISPECIFIC ANTIBODY COMPOSITIONS AND METHOD OF USE - The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided. | 10-25-2012 |
| 20120276104 | MULTISPECIFIC MODULAR ANTIBODY - The invention relates to an antibody having at least two specificities to bind a glycoepitope and a receptor of the erbB class on the surface of a tumor cell, thereby crosslinking the glycoepitope and the receptor, which antibody has apoptotic activity effecting cytolysis independent of NK cells, a method of producing such antibody and its use as a therapeutic. | 11-01-2012 |
| 20120276105 | USE OF CYTOKINE EXPRESSION TO PREDICT SKIN INFLAMMATION; METHODS OF TREATMENT - Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23. | 11-01-2012 |
| 20120276106 | KLK-13 ANTIBODY INHIBITOR FOR TREATING DRY EYE - Disclosed herein is a method of treating dry eye with a KLK-13 antibody. | 11-01-2012 |
| 20120294861 | FGFR1 AGONISTS AND METHODS OF USE - The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same. | 11-22-2012 |
| 20120294862 | ANTAGONISTS OF IL-17A, IL-17F, AND IL-23P19 - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease. | 11-22-2012 |
| 20120294863 | Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders - Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject. | 11-22-2012 |
| 20120301472 | REAGENTS AND TREATMENT METHODS FOR AUTOIMMUNE DISEASES - The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22). | 11-29-2012 |
| 20120321626 | MULTI-SPECIFIC FAB FUSION PROTEINS AND METHODS OF USE - The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner. | 12-20-2012 |
| 20120321627 | BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-20-2012 |
| 20120328618 | DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY - The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19×CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose.In some embodiments, a third dose of said antibody is administered for a third period of time. This dosage regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The present invention also relates to the use of a CD19×CD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method of the present invention. A pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody as defined in the methods/dosage regimen of the present invention is disclosed as well. | 12-27-2012 |
| 20120328619 | Trispecific Therapeutics Against Acute Myeloid Leukaemia - The present invention relates to a molecule having binding specificities for (a) CD123; (b) CD16 and (c) CD33. The present invention further relates to the molecule of the invention, wherein the molecule comprises a first immunoglobulin domain comprising a V | 12-27-2012 |
| 20130004498 | DOSING FOR TREATMENT WITH ANTI-EGFL7 ANTIBODIES - The present invention concerns dosing of anti-EGFL7 antibodies for cancer therapy. | 01-03-2013 |
| 20130011401 | SOLUBLE PROTEINS FOR USE AS THERAPEUTICS - The present invention relates to soluble SIRPα binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble SIRPα binding protein comprising a complex of two heterodimers, wherein each heterodimer essentially consists of:
| 01-10-2013 |
| 20130017200 | MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS, AND METHODS - Multispecific antibodies that specifically bind at least two different epitopes are provided. Structural variants of native antibodies (antibody analogs) are also provided. Also provided are multispecific antibodies and antibody analogs having a range of biological activities. Agonist and antagonist multispecific antibodies and agonist and antagonist antibody analogs are provided. Multispecific antibodies and antibody analogs conjugated with therapeutic and/or diagnostic agents are also provided, as are multispecific antibodies and antibody analogs conjugated with agents to increase in vivo half-life compared to multispecific antibodies and antibody analogs lacking such agents. In addition, methods of making multispecific antibodies and antibody analogs and compositions comprising multispecific antibodies and antibody analogs are provided. Therapeutic, research, and diagnostic uses of multispecific antibodies and antibody analogs are also provided. | 01-17-2013 |
| 20130017201 | BISPECIFIC MONOCLONAL ANTIBODY CAPABLE OF CROSS REACTING WITH LETHAL FACTOR (LF) AND EDEMA FACTOR (EF), AND NEUTRALIZING EDEMA TOXIN (ET) AS WELL AS LETHAL TOXIN (LT) OF BACILLUS ANTHRACISAANM Bhatnagar; RakeshAACI New DelhiAACO INAAGP Bhatnagar; Rakesh New Delhi INAANM Kulshreshtha; ParulAACI New DelhiAACO INAAGP Kulshreshtha; Parul New Delhi IN - The present invention relates to a monoclonal antibody (mAb) having capabilities of binding with lethal factor (LF) as well as edema factor (EF), and neutralizing lethal toxin (LT) as well as edema toxin (ET) of | 01-17-2013 |
| 20130022601 | TRIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 01-24-2013 |
| 20130039913 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF - Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins. | 02-14-2013 |
| 20130058936 | BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE - The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 03-07-2013 |
| 20130058937 | Bispecific antigen binding molecules - The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 03-07-2013 |
| 20130064822 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 03-14-2013 |
| 20130064823 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES - The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding do mains for two different binding sites of LRP6 and compositions and methods of use thereof. | 03-14-2013 |
| 20130078247 | BISPECIFIC BINDING MOLECULES BINDING TO DII4 AND ANG2 - Bispecific binding molecules binding to both DII4 and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with DII4- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described. | 03-28-2013 |
| 20130078248 | BISPECIFIC BINDING MOLECULES BINDING TO VEGF AND ANG2 - Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described. | 03-28-2013 |
| 20130078249 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 03-28-2013 |
| 20130078250 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 03-28-2013 |
| 20130084294 | ANTI-CD19 ANTIBODIES AND USES IN B CELL DISORDERS - The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies. | 04-04-2013 |
| 20130084295 | ANTI-INTERFERON-ALPHA ANTIBODIES - The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). | 04-04-2013 |
| 20130089553 | METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES - The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins, heteromultimers and antibody-immunoadhesin chimeras. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis. | 04-11-2013 |
| 20130089554 | RON Binding Constructs and Methods of Use Thereof - This disclosure provides immunoglobulin binding molecules that specifically bind to human macrophage stimulating receptor (MST1 R, also referred to herein as recepteur d'origine Nantaise or RON), including antibodies and monospecific and multispecific single chain binding proteins having one or more other domains, such as one or more antibody constant region domains. Also provided are therapeutic applications of such binding proteins, such as for the treatment of cancer and inflammatory disorders. | 04-11-2013 |
| 20130089555 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 04-11-2013 |
| 20130095106 | USE OF TRIFUNCTIONAL BISPECIFIC AND TRISPECIFIC ANTIBODIES FOR THE TREATMENT OF MALIGNANT ASCITES - The invention describes the use of a pharmaceutical preparation containing a trifunctional bispecific and/or trispecific having the following properties:
| 04-18-2013 |
| 20130101586 | STABLE MULTIPLE ANTIGEN-BINDING ANTIBODY - The invention provides antibodies that bind to multiple antigens, said antibodies having at least two antibody light chain variable domains and two antibody heavy chain variable domains, wherein each light chain variable domain is linked to a heavy chain variable domain to form a VH/VL construct, and wherein at least one of the VH domains comprises a particular amino acid at AHo position 12, 103 and/or 144, and at least one of the VL domains comprises a particular amino acid at AHo position 47 and/or 50. Nucleic acid molecules, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them, and the use of said antibodies in medicine are also disclosed. | 04-25-2013 |
| 20130108639 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | 05-02-2013 |
| 20130108640 | ANTIKINE ANTIBODIES THAT BIND TO MULTIPLE CC CHEMOKINES | 05-02-2013 |
| 20130115214 | NEUROPILIN ANTAGONISTS - Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications. | 05-09-2013 |
| 20130115215 | DOMAIN INSERTION IMMUNOGLOBULIN - Described herein is an antibody format, which is amenable to bispecific antibody creation. This format is referred to herein as “Domain Insertion Immunoglobulin G” or “(Di-IgG)”. The Di-IgG molecules are capable of specifically binding two different antigens simultaneously, show high level recombinant expression, and are sufficiently aggregation-free to be amenable to commercial production. Further described herein are, Di-IgG-encoding nucleic acids and vectors, host cells for making Di-IgGs, Di-IgG pharmaceutical compositions, and methods of treatment. | 05-09-2013 |
| 20130122007 | Compositions and Methods for Increasing Muscle Mass and Muscle Strength by Specifically Antagonizing GDF8 and or Activin A - The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity. | 05-16-2013 |
| 20130129732 | METHOD FOR PRESERVING FOOD - Method for producing microbially stabilized foods characterized in that a food containing a dialkyl dicarbonate is treated by means of electroporation. | 05-23-2013 |
| 20130129733 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 05-23-2013 |
| 20130129734 | COMPOSITION AND METHODS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LEUKEMIA - The present disclosure relates generally to compositions and methods for the diagnosis, prognosis and treatment of leukemia, in particular leukemia in which leukemic cells, or neoplastic precursors thereof, express Fat1 or a homolog of Fat1 that is substantially not expressed on normal blood cells. | 05-23-2013 |
| 20130129735 | ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE - The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies. | 05-23-2013 |
| 20130149307 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 06-13-2013 |
| 20130149308 | ANTIBODIES TO IL-1BETA AND IL-18, FOR TREATMENT OF DISEASE - The present invention relates to compositions and methods for treatment of disease. More particularly, the present invention relates to anti-IL-1β and anti-IL-18 antibodies, including anti-IL-1β and anti-IL-18 bispecific antibodies, and methods of treating disease using such antibodies. | 06-13-2013 |
| 20130156769 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 06-20-2013 |
| 20130156770 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 06-20-2013 |
| 20130156771 | FDF03 ANTIBODIES AND USES THEREOF - The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer. | 06-20-2013 |
| 20130156772 | Bispecific Anti ErbB1 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 06-20-2013 |
| 20130156773 | LUNG REGENERATION USING CORD BLOOD-DERIVED HEMATOPOIETIC STEM CELLS - Described herein are novel approaches for regenerating injured or defective lung epithelium for the treatment of respiratory disorders using, in part, cord blood-derived hematopoietic stem cells. The methods and uses described herein relate to the administration of or use of hematopoietic stem cells, specifically those isolated or enriched from umbilical cord blood, to a subject in need thereof having a respiratory disorder, such as BPD, or any disorder characterized by insufficient or defective or injured lung epithelium or lung vasculature. | 06-20-2013 |
| 20130156774 | BI-SPECIFIC ANTIBODIES AGAINST TIM-3 AND PD-1 FOR IMMUNOTHERAPY IN CHRONIC IMMUNE CONDITIONS - Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer. | 06-20-2013 |
| 20130164293 | BISPECIFIC BINDING AGENTS - The invention relates to bispecific anti-sclerostin/anti-DKK1 binding agents and combinations of anti-sclerostin and anti-DKK1 binding agents, and related methods of treatment. | 06-27-2013 |
| 20130164294 | SUBSTANCE SPECIFIC TO HUMAN PD-1 - The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy. | 06-27-2013 |
| 20130164295 | VEGF/DLL4 Binding Agents and Uses Thereof - The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 06-27-2013 |
| 20130164296 | Excipients for Stabilising Viral Particles, Polypeptides or Biological Material - A sterile pharmaceutically acceptable aqueous solution, which solution is provided in a sealed container and comprises: a pharmaceutically acceptable aqueous solvent; viral particles or a physiologically active polypeptide; an excipient selected from a polyethyleneimine; a compound of formula (I) or a physiologically acceptable salt or ester thereof; or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and optionally, one or more sugars. | 06-27-2013 |
| 20130171145 | METHODS OF TREATING LIVER DISEASE - Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors. | 07-04-2013 |
| 20130171146 | DUAL-SPECIFIC IL-1A/ IL-1B ANTIBODIES - The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-1α and human IL-1β. The dual specific antibodies of the invention also neutralize both human IL-1α and human IL-1β. The invention also provides domain antibodies (dAbs) specific for human IL-1α and human IL-1β. | 07-04-2013 |
| 20130183311 | BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY - Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agents are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided. | 07-18-2013 |
| 20130183312 | MODULAR TARGETED THERAPEUTIC AGENTS AND METHODS OF MAKING SAME - Provided herein are methods for making targeted therapeutics. In several embodiments, the therapeutics are directed against soluble agents such as toxins, venoms, and/or other factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments, the therapeutics are directed to patient-specific disease markers. In several embodiments, the methods comprise screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. | 07-18-2013 |
| 20130189263 | ANTIGEN-BINDING MOLECULE AND USES THEREOF - In one aspect, the present invention relates to an antigen-binding molecule specific for albumin and CD3 which may comprise two polypeptide chains, each polypeptide chain having at least four variable domains in an orientation preventing Fv formation and the two polypeptide chains are dimerized with one another thereby forming a multivalent antigen-binding molecule. On each of the two polypeptide chains the four variable domains may be arranged in the order V | 07-25-2013 |
| 20130189264 | A NOVEL CHIMERIC PROTEIN FOR PREVENTION AND TREATMENT OF HIV INFECTION - This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker. | 07-25-2013 |
| 20130195870 | ERBB3 Mutations In Cancer - The present invention concerns somatic ErbB3 mutations in cancer including methods of identifying, diagnosing, and prognosing ErbB3 cancers, as well as methods of treating cancer, including certain subpopulations of patients. | 08-01-2013 |
| 20130195871 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins that bind two different (e.g., nonoverlapping) epitopes of the same receptor or two different receptors expressed on the same cell are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 08-01-2013 |
| 20130195872 | ANTI-IL-17A/IL-17F CROSS-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF - This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 08-01-2013 |
| 20130202606 | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same - The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC. | 08-08-2013 |
| 20130209468 | Use of MIF and MIF Pathway Agonists - The present invention relates to novel methods and compositions for increasing AMPK activity and glucose uptake comprising administering a macrophage migration inhibitory factor (MIF) pathway agonist in a subject in need thereof. The invention also relates to methods for selecting a subject for treatment with an agonist of MIF, identifying a subject at risk for developing a condition in which increased AMPK activity is desirable, and for predicting whether a subject is susceptible to a condition in which increased AMPK activity is desirable. | 08-15-2013 |
| 20130209469 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 08-15-2013 |
| 20130209470 | ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation. | 08-15-2013 |
| 20130216544 | Anti-La antibodies and their use for immunotargeting - The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumour cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumour cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumour cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: i. a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and ii. a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein. | 08-22-2013 |
| 20130224205 | MULTISPECIFIC DEIMMUNIZED CD3-BINDERS - The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention. | 08-29-2013 |
| 20130224206 | COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY - This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits. | 08-29-2013 |
| 20130224207 | IDENTIFICATION OF ANTIBODIES SPECIFIC FOR LYSSAVIRUSES AND METHODS OF THEIR USE - Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses. | 08-29-2013 |
| 20130230524 | Protein Involved in Ovarian Cancer - The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCP1 and agents which interact with or modulate the expression or activity of CDCP1 or which modulate the expression of the nucleic acid which codes for CDCP1. | 09-05-2013 |
| 20130230525 | PROTEIN COMPLEXES FOR ANTIGEN BINDING AND METHODS OF USE - Provided herein in certain embodiments are polypeptide complexes capable of binding to an antigen. Pharmaceutical compositions, method of using the polypeptide complexes are also provided. | 09-05-2013 |
| 20130236458 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-13 AND/OR IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 09-12-2013 |
| 20130236459 | MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES - Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided. | 09-12-2013 |
| 20130236460 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-12-2013 |
| 20130236461 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-12-2013 |
| 20130236462 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-12-2013 |
| 20130236463 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-12-2013 |
| 20130236464 | ANTI-CLTA4, ANTI-GLUT2 PROTEIN FOR THE TREATMENT OF TYPE 1 DIABETES - The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic β-cells. | 09-12-2013 |
| 20130243772 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40 - The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 09-19-2013 |
| 20130243773 | RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES - Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields. | 09-19-2013 |
| 20130243774 | NOTCH1 BINDING AGENTS AND METHODS OF USE THEREOF - The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia. | 09-19-2013 |
| 20130243775 | MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells. | 09-19-2013 |
| 20130243776 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-19-2013 |
| 20130243777 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-19-2013 |
| 20130243778 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-19-2013 |
| 20130251716 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-26-2013 |
| 20130251717 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-26-2013 |
| 20130251718 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-26-2013 |
| 20130259866 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 10-03-2013 |
| 20130259867 | DIAGNOSIS AND TREATMENTS RELATING TO HER3 INHIBITORS - The present application describes the use of NRG1 overexpression as a selection criterion for treating cancer patients with a HER3 inhibitor, such as a bispecific HER3/EGFR inhibitor, and methods of treating those patients. | 10-03-2013 |
| 20130259868 | Ang-2 Binding Complexes and Uses Thereof - Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffold's including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described. | 10-03-2013 |
| 20130266568 | ACTIVATABLE BISPECIFIC ANTIBODIES - The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor- or inflammation-specific proteases, and the preparation and use of such bispecific antibodies. | 10-10-2013 |
| 20130266569 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER - An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody. | 10-10-2013 |
| 20130266570 | Targeting Intracellular Target-binding Determinants with Intracellular Antibodies - The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target. | 10-10-2013 |
| 20130266571 | THREE-DIMENSIONAL STRUCTURE OF COMPLEMENT RECEPTOR TYPE 2 AND USES THEREOF - Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds. | 10-10-2013 |
| 20130273053 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria - In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In another aspect, the invention provides methods and compositions for increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent. | 10-17-2013 |
| 20130273054 | Bispecific Anti ErbB2/Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-2 and against human C-met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 10-17-2013 |
| 20130273055 | AGENTS AND METHODS FOR TREATING DISEASES THAT CORRELATE WITH BCMA EXPRESSION - A bispecific binding agent comprising at least two binding domains, wherein a first binding domain binds to the B cell maturation antigen BCMA and wherein a second binding domain binds to CD3, pharmaceutical compositions containing such agent and use for the treatment of plasma cell disorders or B cell disorders which correlate with BCMA expression. | 10-17-2013 |
| 20130280256 | ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES - Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM). | 10-24-2013 |
| 20130287776 | ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME - The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies. | 10-31-2013 |
| 20130287777 | ST2L Antagonists and Methods of Use - The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing. | 10-31-2013 |
| 20130287778 | MEANS AND METHODS FOR TREATING DLBCL - The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient. | 10-31-2013 |
| 20130287779 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 10-31-2013 |
| 20130287780 | PRODUCTS AND METHODS TO PREVENT INFECTIONS - The present invention relates to products and methods for preventing, ameliorating and/or treating infections and other diseases. In one aspect, the products of the present invention relates to compositions comprising germ free colostrum. In another aspect, the products of the present invention relates to compositions comprising synthetically multimerised immunoglobulins. In a third aspect, the products of the present invention relates to compositions comprising germ free colostrum enriched with synthetically multimerised immunoglobulins. The invention also relates to use of said compostions as a pharmaceutical e.g. for prophylactic or ameliorating treatment of infections and other diseases. In addition the invention comprises methods for production of said compositions. | 10-31-2013 |
| 20130295097 | Human Antibodies to Fel d1 and Methods of Use Thereof - The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen. | 11-07-2013 |
| 20130295098 | MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF - The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases. | 11-07-2013 |
| 20130302336 | DISULFIDE STABILIZED DVD-IG MOLECULES - A re-epoxidized polyfunctional epoxy resin composition comprising the reaction product of: (I) an epoxidized polyfunctional epoxy resin oligomeric composition comprising a polyfunctional aliphatic or cycloaliphatic epoxy resin which has been isolated from an epoxy resin product formed as a result of an epoxidation process comprising the reaction of: (i) an aliphatic or cycloaliphatic hydroxyl-containing material; (ii) an epihalohydrin, (iii) a basic-acting substance, in the presence of (iv) a non-Lewis acid catalyst; and (v) optionally, one or more solvents; (II) an epihalohydrin; (III) a basic acting substance; in the presence of (IV) a non-Lewis acid catalyst; and (V) optionally, one or more solvents. A curable epoxy resin composition of the re-epoxidized polyfunctional epoxy resin composition and a thermoset of the curable composition is also disclosed. | 11-14-2013 |
| 20130309234 | CORRELATION OF DE NOVO-INDUCED TUMOR-ASSOCIATED HUMORAL IMMUNE RESPONSES WITH IMPROVED CLINICAL OUTCOME - The present invention refers to a method for predicting an improved therapeutic benefit for an individual suffering from a tumor carrying a known tumor-associated cell surface antigen (such as EpCAM). The present invention further refers to a method for the induction of secondary humoral immune responses directed against a second tumor-associated antigen (e.g., another tumor-associated antigen, like HER2/neu) different from the first tumor-associated antigen in an individual suffering from a tumor comprising tumor cells expressing the first tumor-associated antigen, e.g., EpCAM.) | 11-21-2013 |
| 20130309235 | ANTAGONISTS OF IL-17A, IL-17F, AND IL-23P19 - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease. | 11-21-2013 |
| 20130309236 | ANTI-INTERFERON-ALPHA ANTIBODIES - The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of TUN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). | 11-21-2013 |
| 20130315910 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 11-28-2013 |
| 20130315911 | BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 11-28-2013 |
| 20130323250 | ANTI-CLTA4, ANTI-GLUT2 PROTEIN FOR THE TREATMENT OF TYPE 1 DIABETES - The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic β-cells. | 12-05-2013 |
| 20130323251 | USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE - Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity. | 12-05-2013 |
| 20130330345 | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII - Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered. | 12-12-2013 |
| 20130330346 | Chemokine receptor binding polypeptides - The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2. | 12-12-2013 |
| 20130336980 | ST2L Antagonists and Methods of Use - The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing. | 12-19-2013 |
| 20130336981 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES - The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided. | 12-19-2013 |
| 20130344071 | Class I Anti-CEA Antibodies and Uses Thereof - The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer. | 12-26-2013 |
| 20130344072 | Anti-VEGF-C Antibodies and Methods Using Same - The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression. | 12-26-2013 |
| 20130344073 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders - In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent. | 12-26-2013 |
| 20130344074 | USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN - Uses of a dual V region antibody-like protein or a fragment of a dual V region antibody-like region. | 12-26-2013 |
| 20140017243 | USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS - The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism. | 01-16-2014 |
| 20140017244 | Bispecific Anti-VEGF/Anti-ANG-2 Antibodies and their use in the Treatment of Ocular Vascular Diseases - The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 01-16-2014 |
| 20140017245 | KLK-13 ANTIBODY INHIBITOR FOR TREATING DRY EYE - Disclosed herein is a method of treating dry eye with a KLK-13 antibody. | 01-16-2014 |
| 20140017246 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 01-16-2014 |
| 20140023649 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 01-23-2014 |
| 20140037631 | ANTIGEN BINDING FORMATS FOR USE IN THERAPEUTIC TREATMENTS OR DIAGNOSTIC ASSAYS - The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody. | 02-06-2014 |
| 20140037632 | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered. | 02-06-2014 |
| 20140044719 | ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS OF USE - Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided. | 02-13-2014 |
| 20140044720 | HUMAN MONOCLONAL ANTIBODIES THAT BIND INSULIN-LIKE GROWTH FACTOR (IGF) I AND II - Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer. | 02-13-2014 |
| 20140050730 | METHODS FOR DIAGNOSING AND TREATING NEUROENDOCRINE CANCER - The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed. | 02-20-2014 |
| 20140056895 | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation - The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins. | 02-27-2014 |
| 20140056896 | ANTI-CD19 ANTIBODIES AND USES IN B CELL DISORDERS - The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies. | 02-27-2014 |
| 20140056897 | BISPECIFIC THREE-CHAIN ANTIBODY-LIKE MOLECULES - The present invention relates to novel bispecific three-chain antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific three-chain antibody-like molecules (TCAs) capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases. | 02-27-2014 |
| 20140056898 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering either i) an effective amount of an anti-estrogen agent or ii) an effective amount of a receptor tyrosine kinase inhibitor and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody, and optionally an effective amount trastuzumab. Also disclosed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use in the therapy of a tumor in combination with either i) an anti-estrogen agent or ii) a receptor tyrosine kinase inhibitor, and optionally in use with trastuzumab. | 02-27-2014 |
| 20140056899 | ANTI-HER ANTIBODIES - The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists. | 02-27-2014 |
| 20140065147 | Use of Cytokine Expression to Predict Skin Inflammation; Methods of Treatment - Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23. | 03-06-2014 |
| 20140065148 | TREATMENT METHODS USING ANTIBODIES TO AMINOPHOSPHOLIPIDS - Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach. | 03-06-2014 |
| 20140065149 | Methods for Treating Melanoma - Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described. | 03-06-2014 |
| 20140079703 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or TMD1, and/or combinations thereof; and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody. Also disclosed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use in the therapy of a tumor in combination with an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or TMD1, and/or combinations thereof. | 03-20-2014 |
| 20140079704 | BI-Specific Diabodies For Masking And Targeting Vaccines - The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further enhance the efficacy of those immune responses. | 03-20-2014 |
| 20140079705 | BISPECIFIC IMMUNOBINDERS DIRECTED AGAINST TNF AND IL-17 - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 03-20-2014 |
| 20140086922 | ANTI-IL-12/IL-23 ANTIBODIES - Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12Rβ2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12Rβ1. | 03-27-2014 |
| 20140105899 | ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME - The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes. | 04-17-2014 |
| 20140112926 | Fc VARIANTS - Disclosed are Fc-containing proteins comprising a binding region and a variant Fc region that can elicit one or more immune effector function and/or bind to an Fc receptor more effectively than a similar Fc-containing protein comprising a wild type Fc region. Also disclosed are nucleic acids encoding such Fc-containing proteins, methods for making such proteins, and methods of treatment utilizing such proteins. | 04-24-2014 |
| 20140112927 | BISPECIFIC MONOCLONAL ANTIBODY THERAPEUTICS AGAINST WEST NILE VIRUS WITH IMPROVED CNS PENETRATION - The plant-based production of a therapeutic antibody against West Nile Virus is disclosed. | 04-24-2014 |
| 20140120095 | BISPECIFIC BINDING MOLECULES FOR ANTI-ANGIOGENESIS THERAPY - Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a DII4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and DII4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same. | 05-01-2014 |
| 20140120096 | BISPECIFIC IGG ANTIBODIES AS T CELL ENGAGERS - Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided. | 05-01-2014 |
| 20140127209 | ANTIBODY DERIVATIVES - The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 antibodies and anti-IL-23 antibodies. | 05-08-2014 |
| 20140127210 | BISPECIFIC ANTIGEN BINDING PROTEIN COMPLEX AND PREPARATION METHODS OF BISPECIFIC ANTIBODIES - A bispecific antigen binding protein complex comprising a first polypeptide comprising a first antigen binding site at an N terminus; a second polypeptide comprising a second antigen binding site at an N terminus; and a linker connecting the first polypeptide and the second polypeptide; wherein the linker comprises a tag at one terminus thereof, and wherein the tag is connected to a C-terminus of the first polypeptide or to an N-terminus of the second polypeptide, and comprises a cleavable amino acid sequence; as well as related compositions and methods. | 05-08-2014 |
| 20140134170 | USE OF INHIBITORS OF EGFR-FAMILY RECEPTORS IN THE TREATMENT OF HORMONE REFRACTORY BREAST CANCERS - Provided are methods of suppressing growth of hormone refractory breast tumors by contacting tumor cells with an ErbB3 inhibitor, preferably an anti-ErbB3 antibody. Also provided are methods for treating hormone refractory breast cancer in a patient by administering to the patient an inhibitor of heregulin binding to ErbB3 or to ErbB2/ErbB3 heterodimer, which inhibitor is an anti-ErbB3 antibody or an anti-ErbB2 antibody. The treatment methods can further comprise selecting a patient having a hormone refractory breast cancer and then administering the inhibitor to the patient. The treatment methods may also comprise administering an estrogen receptor antagonist, or an aromatase inhibitor to the patent and may at further comprise administering to the patient at least one additional anti-cancer agent that is not an ErbB3 inhibitor, an estrogen receptor antagonist, or an aromatase inhibitor to the patient in combination with the ErbB3 inhibitor. | 05-15-2014 |
| 20140134171 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 05-15-2014 |
| 20140134172 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 05-15-2014 |
| 20140140998 | CLEAVAGE INHIBITORS OF TRANSFORMING GROWTH FACTOR BETA TYPE I RECEPTOR AND USES THEREOF IN CANCER THERAPY - Disclosed herein are methods to inhibit cleavage of a type I receptor of transforming growth factor beta (TβRI) and reduce cancer cell invasiveness/metastasis, and agents and pharmaceutical compositions for use in these methods. Also disclosed herein are methods for identifying agents that inhibit cleavage of TβRI and methods for diagnosing and/or prognosing cancer based on nuclear localization of a intracellular domain of TβRI, which is a product of TβRI cleavage. | 05-22-2014 |
| 20140140999 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES - The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided. | 05-22-2014 |
| 20140141000 | Bispecific EGFR/C-Met Antibodies - Bispecific EGFR/c-Met antibodies and methods of making and using the molecules. | 05-22-2014 |
| 20140147443 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER - An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody. | 05-29-2014 |
| 20140154252 | SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION - Variations on the structural themes for multivalent binding molecules with effector function, or scorpions, will be apparent to those of skill in the art upon review of the present disclosure, and such variant structures are within the scope of the invention. | 06-05-2014 |
| 20140154253 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs - Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3. | 06-05-2014 |
| 20140154254 | HETERODIMERIC IMMUNOGLOBULINS - The present application is directed to heterodimeric antibodies and methods of use. | 06-05-2014 |
| 20140154255 | ANTI-VEGF ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF. | 06-05-2014 |
| 20140154256 | ANTI-IL1ALPHA/BETA DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 06-05-2014 |
| 20140161804 | BISPECIFIC IMMUNOBINDERS DIRECTED AGAINST TNF AND IL-17 - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 06-12-2014 |
| 20140161805 | Methods for Manipulating Phagocytosis Mediated by CD47 - Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable. | 06-12-2014 |
| 20140170148 | BISPECIFIC ANTIBODIES AGAINST HER2 - Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed. | 06-19-2014 |
| 20140170149 | BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3 - Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed. | 06-19-2014 |
| 20140178388 | MULTIVALENT ANTIBODY FRAGMENTS AND TRIMERIZED COMPLEXES THEREOF - The present invention relates to a method for producing multivalent Fab fragments. In particular, the invention relates to a method for the generation of trimeric Fab fragments by co-expression of a gene construct comprising a heavy chain portion of a Fab fragment and an in-frame fused collagen-like peptide, and a gene construct consisting of a light chain portion of an IgG in mammalian cells. Uses of molecules generated using the method of the invention are also described. | 06-26-2014 |
| 20140178389 | IL-1 BINDING PROTEINS - The disclosure provides binding proteins that specifically bind to IL-1α and IL-1β. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1α and/or IL-1β and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation. | 06-26-2014 |
| 20140186354 | ANTI-HER3/HER4 ANTIBODIES BINDING TO THE BETA-HAIRPIN OF HER3 AND THE BETA-HAIRPIN OF HER4 - The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament. | 07-03-2014 |
| 20140186355 | Nucleic Acids Encoding Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 07-03-2014 |
| 20140193414 | ANTI-HER ANTIBODIES - The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists. | 07-10-2014 |
| 20140193415 | BISPECIFIC ANTI-EGFR/ANTI IGF-1R ANTIBODIES - The present invention relates to bispecific anti-EGFR/anti IGF-1R antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 07-10-2014 |
| 20140199312 | DDR1-Binding Agents and Methods of Use Thereof - The present invention relates to DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The present invention further provides methods of using agents that modulate the activity of DDR1, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 07-17-2014 |
| 20140212423 | BLOOD-BRAIN BARRIER PENETRATING DUAL SPECIFIC BINDING PROTEINS - Engineered multivalent and multispecific binding proteins capable of penetrating the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 07-31-2014 |
| 20140212424 | ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-α. | 07-31-2014 |
| 20140212425 | THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR INDUCING TROGOCYTOSIS - Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, the antibodies induce trogocytosis of B-cell antigens, such as CD19, CD20, CD21, CD22, CD79b, CD44, CD62L, or β7-integrin. Trogocytosis may play a significant role in determining antibody efficacy, disease responsiveness and prognosis of therapeutic intervention and trogocytosis-dependent responses may be monitored by measuring the levels of trogocytosis of one or more B-cell surface antigens induced by the bispecific antibody. | 07-31-2014 |
| 20140220019 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 08-07-2014 |
| 20140220020 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 08-07-2014 |
| 20140220021 | THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES COMPRISING PD-1 AGONIST - Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 μg/kg, and (c) without requiring administration for at least 3 months after the last administration. | 08-07-2014 |
| 20140234317 | METHODS FOR PREVENTING TOXIC DRUG-DRUG INTERACTIONS IN COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Methods are disclosed for preventing toxic drug-drug interactions during combination cancer therapy with a drug that is an anti-ErbB3 agent, such as an anti-ErbB3 antibody, together with a drug that is a tyrosine kinase inhibitor and/or a drug that binds to alpha-1 acid glycoprotein (e.g., erlotinib). Health care practitioners obtaining any one of the drugs are warned that when co-administering the drug that is an anti-ErbB3 agent with either or both of a drug that is a tyrosine kinase inhibitor and a drug that binds to alpha-1 acid glycoprotein, at least one of the co-administered drugs should be administered using a reduced dosage to prevent toxicity. In a reduced dosage, the amount of drug administered per unit time is reduced as compared to a dose that would be administered if the drug was administered as monotherapy. The reduced dosage can be, for example, a reduced drug dose or a reduced drug dosing frequency, or both. Compositions useful in practicing the disclosed methods are also provided. | 08-21-2014 |
| 20140242075 | ANTIBODY VARIANTS AND USES THEREOF - Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response. | 08-28-2014 |
| 20140242076 | MULTISPECIFIC MUTATED ANTIBODY FAB FRAGMENTS - The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing. | 08-28-2014 |
| 20140242077 | METHODS AND COMPOSITIONS FOR MODULATING AN IMMUNE RESPONSE - Provided are multispecific binding proteins and methods for using these multispecific binding proteins to modulate the activation state of immune cells, such as T-cells (e.g., cytotoxic T-cells). Also provided are methods of modulating an immune response (e.g., cell killing by cytotoxic T-cells) in a subject (e.g., a human subject). Also provided are nucleic acids, expression vectors and host cells encoding the multispecific binding proteins. | 08-28-2014 |
| 20140242078 | METHODS AND MONITORING OF TREATMENT WITH A WNT PATHWAY INHIBITOR - Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity. | 08-28-2014 |
| 20140242079 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 08-28-2014 |
| 20140242080 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 08-28-2014 |
| 20140242081 | DOSING REGIMENS FOR TREATMENT OF CEA-EXPRESSING CANCERS - The present disclosure provides compositions and methods for treating CEA-expressing cancers. Methods for dosing a patient with an antibody that binds to CEA and human CD3 are also provided. | 08-28-2014 |
| 20140255405 | Removal of Monomeric Targets - The present invention relates to a novel method for the removal of monomeric targets from bodily fluids, and to pharmaceutical compositions for use in such methods. | 09-11-2014 |
| 20140255406 | ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES - Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNFα) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS). | 09-11-2014 |
| 20140255407 | Bispecific Molecules That Are Immunoreactive with Immune Effector Cells of a Companion Animal That Express an Activating Receptor and Cells That Express B7-H3 and Uses Thereof - The present invention relates to bispecific molecules that are immunoreactive to an activating receptor of a companion animal immune effector cell and to B7-H3, and to the use of such bispecific molecules in the treatment of cancer in companion animals. | 09-11-2014 |
| 20140255408 | Bispecific EGFR/C-Met Antibodies - Bispecific EGFR/c-Met antibodies and methods of making and using the molecules. | 09-11-2014 |
| 20140271647 | Pan-ELR+ CXC CHEMOKINE ANTIBODIES - Antibodies are provided that specifically bind seven human ELR | 09-18-2014 |
| 20140271648 | Interferon Alpha and Omega Antibody Antagonists - Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFNα and IFNω. | 09-18-2014 |
| 20140271649 | METHODS AND COMPOSITIONS FOR INHIBITING STAPHYLOCOCCUS AGGLUTINATION IN BLOOD - Certain embodiments are directed to methods of inhibiting Staphylococcal infection comprising administering effective amounts of a ClfA inhibitor and a thrombin inhibitor to a patient. | 09-18-2014 |
| 20140286951 | MET-BINDING AGENTS AND USES THEREOF - The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer. | 09-25-2014 |
| 20140294832 | MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI) - Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. | 10-02-2014 |
| 20140294833 | NOVEL HETERODIMERIC PROTEINS - The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different. | 10-02-2014 |
| 20140294834 | TANDEM FC BISPECIFIC ANTIBODIES - Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific. | 10-02-2014 |
| 20140294835 | NOVEL HETERODIMERIC PROTEINS - The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different. | 10-02-2014 |
| 20140294836 | TARGETING REGULATORY T CELLS WITH HETERODIMERIC PROTEINS - The present invention provides methods and compositions comprising a heterodimeric antibody comprising a first monomer comprising a first variant heavy chain constant region and an anti-CD4 binding moiety. The heterodimeric antibody also comprises a second monomer comprising: a second variant heavy chain constant region and an anti-CD25 binding moiety. In some cases, the pIs of the first and second variant heavy chain constant regions are at least 0.5 logs apart. | 10-02-2014 |
| 20140294837 | FUSION PROTEIN COMPRISING ANTI-C-MET ANTIBODY AND VEGF-BINDING FRAGMENT - There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment. | 10-02-2014 |
| 20140294838 | BISPECIFIC ANTI-CMET/ANTI-HER2 ANTIBODIES - There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same. | 10-02-2014 |
| 20140294839 | Methylated Peptides Derived from Tau Protein and Their Antibodies for Diagnosis and Therapy of Alzheimer's Disease - In sporadic Alzheimer's disease, neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. Immunoassays have been developed recently that detect tau in biological specimens, thus providing a means for pre-mortem diagnosis of Alzheimer's disease, which has remained elusive. These assays have been improved by the analysis of relevant post-translational modifications, such as phosphorylation, however opportunity for improvement remains. The present invention addresses this issue by disclosing synthetic methylated peptides derived from the tau protein of paired helical filaments and non-diseased control brain. Alzheimer's disease specificity is provided by the presence or absence of methyl moieties on lysine residues and differences between mono-, di-, and tri-methylation. The methylated peptide is useful as an antigen and a binding partner for identifying compounds that interact with the peptide and the methylated tau protein, including antibodies that can distinguish non-diseased brain from that affected by Alzheimer's disease. The resulting antibodies are useful diagnostically and therapeutically. The compounds that specifically bind to methylated tau proteins are useful for eliminating abnormally methylated tau. | 10-02-2014 |
| 20140302034 | NOVEL MODULATORS AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided. | 10-09-2014 |
| 20140302035 | ANTI-C-MET Tandem Fc Bispecific Antibodies - Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific. | 10-09-2014 |
| 20140302036 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 - Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins. | 10-09-2014 |
| 20140302037 | BISPECIFIC-Fc MOLECULES - Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules. | 10-09-2014 |
| 20140302038 | MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF - The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins. | 10-09-2014 |
| 20140308285 | HETERODIMERIC BISPECIFIC ANTIBODIES - Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety. | 10-16-2014 |
| 20140308286 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 10-16-2014 |
| 20140314763 | CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES - The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses. | 10-23-2014 |
| 20140314764 | BI-SPECIFIC ANTIBODIES FOR MEDICAL USE - A bispecific antibody format devoid of an active Fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on B-cells, for use in the treatment or prevention of B cell mediated autoimmune diseases. | 10-23-2014 |
| 20140322221 | MULTIVALENT ANTIBODIES AND USES THEREFOR - The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies. | 10-30-2014 |
| 20140335089 | ANTIGEN-BINDING MOLECULE FOR PROMOTING ELIMINATION OF ANTIGENS - The present inventors created antigen-binding molecules containing an antigen-binding domain and an Fcγ-receptor-binding domain, wherein the molecules have human-FcRn-binding activity in an acidic pH range condition, the antigen-binding domain changes the antigen-binding activity of the antigen-binding molecules depending on the ion-concentration condition, and the Fcγ receptor-binding domain has higher binding activity to the Fcγ receptor in a neutral pH range condition than an Fc region of a native human IgG in which the sugar chain bound at position 297 (EU numbering) is a fucose-containing sugar chain. | 11-13-2014 |
| 20140341906 | HETERODIMERIC FC REGIONS, BINDING MOLECULES COMPRISING SAME, AND METHODS RELATING THERETO - The present invention features inter alia polypeptides comprising heterodimeric Fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject. | 11-20-2014 |
| 20140341907 | BISPECIFIC ANTIBODY FRAGMENTS FOR NEUROLOGICAL DISEASE PROTEINS AND METHODS OF USE - The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases. | 11-20-2014 |
| 20140348832 | INHIBITORS OF T-CELL ACTIVATION - The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex. | 11-27-2014 |
| 20140348833 | NOVEL METHODS AND ANTIBODIES FOR TREATING CANCER - The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein
| 11-27-2014 |
| 20140348834 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 11-27-2014 |
| 20140348835 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 11-27-2014 |
| 20140348836 | ANTI-CD40 ANTIBODIES, USES AND METHODS - The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10 | 11-27-2014 |
| 20140348837 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 11-27-2014 |
| 20140348838 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 11-27-2014 |
| 20140348839 | MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY SCAFFOLDS - The technology relates in part to engineered antibodies. In particular, multispecific engineered antibodies. Such antibodies can be utilized for diagnostic and therapeutic applications in some aspects. | 11-27-2014 |
| 20140356364 | Anti-B7-H4 Antibodies and Their Uses - The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression. | 12-04-2014 |
| 20140356365 | PROGNOSTIC, SCREENING AND TREATMENT METHODS AND AGENTS FOR TREATMENT OF METSTASIS AND INFLAMMATION USING T54 ONCOFOETAL GLYCOPROTEIN - Methods and agents are disclosed based on the finding that 5T4 interacts with CXCR4 in the cell membrane to form a complex, and that the 5T4 transmembrane region is involved in the promotion of CXCR4 membrane expression and chemotactic response. | 12-04-2014 |
| 20140356366 | COMPOSITION FOR TARGET MEMBRANE PROTEIN DEPLETION - A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver membrane protein and target membrane protein are associated with the cell membrane where the target membrane protein positions, and are internalized into a cell and degraded when the first binding domain of the dual binding molecule binds the driver membrane protein; as well as related methods and compositions. | 12-04-2014 |
| 20140363435 | KLOTHO BETA - The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. | 12-11-2014 |
| 20140370018 | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered. | 12-18-2014 |
| 20140370019 | BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5, ANTIBODIES SPECIFIC FOR DR5 AND METHODS OF USE - The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-18-2014 |
| 20140370020 | ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN - It was found that association between CH1 and CL can be suppressed by substituting amino acids that exist on the interface between CH 1 and CL with electrically-charged amino acids, and that formation of heterogeneous molecules is enabled more efficiently than by introducing knobs into holes mutations into CH3 domain. | 12-18-2014 |
| 20140377268 | CLEAVAGE INHIBITORS OF TRANSFORMING GROWTH FACTOR BETA TYPE I RECEPTOR AND USES THEREOF IN CANCER THERAPY - Disclosed herein are methods to inhibit cleavage of a type I receptor of transforming growth factor beta (TβRI) and reduce cancer cell invasiveness/metastasis, and agents and pharmaceutical compositions for use in these methods. Also disclosed herein are methods for identifying agents that inhibit cleavage of TβRI and methods for diagnosing and/or prognosing cancer based on nuclear localization of a intracellular domain of TβRI, which is a product of TβRI cleavage. | 12-25-2014 |
| 20140377269 | MULTIVALENT ANTIBODY ANALOGS, AND METHODS OF THEIR PREPARATION AND USE - Multivalent antibody analogs that co-engage at least two different antigens or epitopes (also referred to “targets”, used interchangeably throughout), are provided, as well as methods for their production and use. | 12-25-2014 |
| 20140377270 | OPTIMIZED ANTIBODY VARIABLE REGIONS - The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. | 12-25-2014 |
| 20150010565 | RSPO BINDING AGENTS AND USES THEREOF - The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 01-08-2015 |
| 20150010566 | INFLUENZA A VIRUS SPECIFIC ANTIBODIES - The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection. | 01-08-2015 |
| 20150010567 | BISPECIFIC ANTIBODY MOLECULES WITH ANTIGEN-TRANSFECTED T-CELLS AND THEIR USE IN MEDICINE - The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8 | 01-08-2015 |
| 20150010568 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFICALLY ANTAGONIZING GDF8 AND OR ACTIVIN A - The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity. | 01-08-2015 |
| 20150017168 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 01-15-2015 |
| 20150017169 | Sequence Asymmetric Modified IgG4 Bispecific Antibodies - The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterised in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation. | 01-15-2015 |
| 20150023965 | METHODS OF TREATING UROTHELIAL CARCINOMA - Methods and compositions for treating a urothelial and/or a micropapillary carcinoma, such as a micropapillary urothelial carcinoma are disclosed. | 01-22-2015 |
| 20150023966 | COMBINATION THERAPIES USING ANTI-PSEUDOMONAS PSL AND PCRV BINDING MOLECULES - This disclosure relates to combination therapies comprising anti- | 01-22-2015 |
| 20150023967 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster3 of BCMA, and the second binding domain is capable of binding to the Tcell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 01-22-2015 |
| 20150030598 | TRI- OR TETRASPECIFIC ANTIBODIES - The present invention relates to tri- or tetraspecific antibodies, their manufacture and use. | 01-29-2015 |
| 20150030599 | ANTI-EGFR ANTIBODY AND ANTI-C-MET/ANTI-EGFR BISPECIFIC ANTIBODIES COMPRISING THE SAME - An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided. | 01-29-2015 |
| 20150037337 | Manipulation of Immunoglobulin Gene Diversity and Multi-Antibody Therapeutics - The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies comprising human variable region sequences. The present invention is directed to the provision of long HCDR3s from non-human vertebrates and cells. The present invention is also directed to the provision of novel V, D and J pairings in immunoglobulin heavy and light chain loci. Novel, biased antibody diversities and potentially expanded diversities are provided. The invention also provides for novel and potentially expanded diversity or diversity that is biased towards variable gene usage common to antibodies useful for treating and/or preventing certain diseases or conditions, such as infectious diseases. The invention also provides methods of generating antibodies using such vertebrates, as well as the antibodies per se, therapeutic compositions thereof and uses. | 02-05-2015 |
| 20150037338 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 02-05-2015 |
| 20150037339 | ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with GDF8 binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis. | 02-05-2015 |
| 20150044214 | BISPECIFIC, TETRAVALENT ANTIGEN BINDING PROTEINS - The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 02-12-2015 |
| 20150044215 | PSEUDOMONAS AERUGINOSA PCRV BINDING SINGLE VARIABLE DOMAIN ANTIBODIES - Polypeptides are provided that are capable of significantly inhibiting andor neutralizing | 02-12-2015 |
| 20150044216 | BISPECIFIC ANTIBODIES - Provided are bispecific antibodies having a full-size antibody portion with two light chains and two heavy chains, wherein the two heavy chains each is fused to a single-chain variable fragment (scFv) portion. In certain embodiments, the full-size antibody has specificity to EGFR and the scFv has specificity to VEGF. | 02-12-2015 |
| 20150044217 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER - Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib. | 02-12-2015 |
| 20150056202 | ANTI-TNF/IL-17 DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 02-26-2015 |
| 20150056203 | Method for Predicting the Risk of A Subject For Contracting Diabetes Mellitus And/Or Metabolic Syndrome Or For Diagnosing Metabolic Syndrome In a Subject - Subject matter of the present invention is a method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject wherein said subject is non-diabetic, comprising the following steps determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of pro-neurotensin or fragments thereof with the risk of said subject for contracting diabetes mellitus and/or metabolic syndrome, wherein an elevated level is predictive for an enhanced risk of getting diabetes mellitus and/or metabolic syndrome, or wherein an elevated level correlates to the diagnosis of metabolic syndrome in a subject wherein said subject is non-diabetic. | 02-26-2015 |
| 20150056204 | DR5 RECEPTOR AGONIST COMBINATIONS - The present invention includes apoptotic compositions and methods for inducing apoptosis of cancer cells independent of NK cells. An apoptotic composition comprises a cooperative combination of antibodies that specifically bind to human DR5, or a cooperative combination of an anti-DR5 antibody and TRAIL. Administration of therapeutically effective amounts of an apoptotic composition induces apoptosis of apoptosis sensitive cancer cells. | 02-26-2015 |
| 20150056205 | STEROID SPARING AGENTS AND METHODS OF USING SAME - This invention relates generally to methods of treating inflammatory bowel diseases (IBD), asthma, Crohn's Disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid-sparing effective amount of an immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions. | 02-26-2015 |
| 20150056206 | MULTI-SPECIFIC FAB FUSION PROTEINS AND METHODS OF USE - The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner. | 02-26-2015 |
| 20150064186 | METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS - Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease. | 03-05-2015 |
| 20150071927 | ANTI-HER2 AND ANTI-IGF-IR BI-SPECIFIC ANTIBODIES AND USES THEREOF - Disclosed are antibodies, or binding fragments thereof, that specifically bind to human HER2 and human IGF-IR. Also provided are nucleic acid molecules encoding the disclosed antibodies and binding fragments and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of HER2 and IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens. | 03-12-2015 |
| 20150071928 | DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY - The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19×CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose. In some embodiments, a third dose of said antibody is administered for a third period of time. This dosage regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The present invention also relates to the use CD19×CD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method of the present invention. A pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody as defined in the methods/dosage regimen of the present invention is disclosed as well. | 03-12-2015 |
| 20150071929 | ANTI-NKG2A ANTIBODIES AND USES THEREOF - Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described. | 03-12-2015 |
| 20150079093 | DUAL ANTIGEN-INDUCED BIPARTITE FUNCTIONAL COMPLEMENTATION - The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “A” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides. | 03-19-2015 |
| 20150086550 | COMBINATION OF THE APPLICATION OF ANTIBODIES FOR IMMUNOSTIMULATION TOGETHER WITH GLUCOCORTICOIDS - The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid. | 03-26-2015 |
| 20150086551 | Novel Therapeutic Agents - The present invention relates to a class of hydroxamic acid compounds of Formula (I), which act as alkylating agents and/or inhibitors of the HDAC pathway, having potential utility in the treatment of a neoplastic disease and immune diseases. | 03-26-2015 |
| 20150086552 | BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 03-26-2015 |
| 20150086553 | POLYPEPTIDE BINDING TO ANNEXIN A1 AND USE THEREOF - A polypeptide binding to Annexin A1, an antagonist against Annexin A1 including the polypeptide, an anti-Annexin A1 antibody including the polypeptide or an antigen-binding fragment thereof, and methods of preventing, treating and/or diagnosing a disease, including administering the antagonist and/or the antibody or an antigen-binding fragment thereof to a subject. | 03-26-2015 |
| 20150086554 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 03-26-2015 |
| 20150093385 | RECOMBINANT ANTIBODIES HAVING DUAL SPECIFICITY FOR GANGLIOSIDES AND USE THEREOF - The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for N-acetyl GM3 and N-glycolyl GM3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens. Likewise, the invention relates to the use of these antibodies in the diagnosis of tumors expressing at least one of the two variants of the GM3 ganglioside. | 04-02-2015 |
| 20150093386 | MULTI-FUNCTIONAL ANTIBODY POLYPEPTIDE FOR CRYPTIC EPITOPE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND T CELL ANTIGEN - Multi-functional antibody polypeptide comprises:
| 04-02-2015 |
| 20150093387 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 04-02-2015 |
| 20150104452 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 04-16-2015 |
| 20150104453 | FDF03 ANTIBODIES AND USES THEREOF - The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer. | 04-16-2015 |
| 20150110788 | BISPECIFIC ANTIBODIES WITH AN FGF2 BINDING DOMAIN - The present invention provides a bispecific antibody having a binding domain that binds to FGF2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. | 04-23-2015 |
| 20150110789 | Bispecific SCFV Immunofusion (BIF) - Certain embodiments are directed to a bispecific immunoglobulin that is capable of binding cell surface molecules on a target cell, such as cancer cells, and cell surface molecules on immune effector cell, such as cytotoxic T lymphocytes, resulting in the targeted killing of target cells. In certain aspects a Bif is a polypeptide comprising a first target binding domain that specifically binds a cancer cell, a second effector binding domain that specifically binds an immunologic effector, and an immunoglobulin constant region linker operatively coupling the first and second binding domain. | 04-23-2015 |
| 20150118233 | MONOVALENT, BIVALENT AND TRIVALENT ANTI HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) NANOBODY CONSTRUCTS FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS - Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. | 04-30-2015 |
| 20150118234 | SUBSTANCE SPECIFIC TO HUMAN PD-1 - The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy. | 04-30-2015 |
| 20150125450 | BISPECIFIC ANTIBODIES THAT NEUTRALIZE BOTH TNF-ALPHA AND IL-6: NOVEL THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE - The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-TNF-α antibody or antigen-binding fragment thereof and at least one anti-IL-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a DNL® complex. The anti-TNF-α or anti-IL-6 antibodies may comprise specific CDR sequences disclosed herein. The compositions and methods are of use to treat autoimmune disease, immune system dysfunction or inflammatory disease, as disclosed herein. | 05-07-2015 |
| 20150132306 | HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES - We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These are promising therapeutic agents. | 05-14-2015 |
| 20150132307 | BISPECIFIC ANTIBODIES AGAINST HUMAN TWEAK AND HUMAN 1L17 AND USES THEREOF - The present invention relates to Bispecific antibodies against human TWEAK and human IL17 (bispecific TWEAK-IL17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof | 05-14-2015 |
| 20150132308 | Combination Therapy Using Anti-EGFR And Anti-HER2 Antibodies - The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer. | 05-14-2015 |
| 20150132309 | KLOTHO BETA - The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. | 05-14-2015 |
| 20150139996 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES - The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided. | 05-21-2015 |
| 20150139997 | ANTI-DR5 FAMILY ANTIBODIES, BISPECIFIC OR MULTIVALENT ANTI-DR5 FAMILY ANTIBODIES AND METHODS OF USE THEREOF - Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells. | 05-21-2015 |
| 20150147326 | PROTEIN BIOMARKER AND USES THEREOF - The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step. | 05-28-2015 |
| 20150147327 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 05-28-2015 |
| 20150291689 | Compositions and Methods for Treating Rheumatoid Arthritis - Proteins that bind both IL-17 and TNF are described along with their use in compositions and methods for treating, preventing, and ameliorating rheumatoid arthritis. | 10-15-2015 |
| 20150291703 | ANTIBODY AND ANTIBODY COMPOSITION PRODUCTION METHOD - [Problem] To provide: an antibody comprising at least two kinds of Fab, and in particular having restricted light chain-heavy chain combinations; a corresponding antibody composition; and production methods for same. [Solution] The present invention provides production methods for (1) an antibody or (2) an antibody composition, the methods using non-natural disulfide bonds. | 10-15-2015 |
| 20150306216 | COMBINATIONS OF A PI3K/AKT INHIBITOR COMPOUND WITH AN HER3/EGFR INHIBITOR COMPOUND AND USE THEREOF IN THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER - The invention provides combinations comprising GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof and ME-HD7945A. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer (e.g., triple negative breast cancer). | 10-29-2015 |
| 20150307594 | ENGINEERED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND USES THEREOF - The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the C H and/or C L domains, one or more amino acid modifications in the V H and/or V L domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first. | 10-29-2015 |
| 20150307609 | OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF - The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided. | 10-29-2015 |
| 20150307629 | Bispecific antibodies that bind to CD38 and CD3 - The invention provides novel heterodimeric proteins including heterodimeric antibodies. | 10-29-2015 |
| 20150315272 | Epitopes of IL-17A and IL-17F And Antibodies Specific Thereto - The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them. | 11-05-2015 |
| 20150315283 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 11-05-2015 |
| 20150315296 | MULTISPECIFIC ANTIBODIES - The present invention relates to multispecific antibodies, their manufacture and use. | 11-05-2015 |
| 20150322149 | BLOOD BRAIN BARRIER SHUTTLE - The present invention relates to blood brain barrier shuttles that bind receptors on the blood brain barrier (R/BBB) and methods of using the same. | 11-12-2015 |
| 20150322162 | ANTI-HER2 ANTIBODY AND ANTI-C-MET/ANTI-HER2 BISPECIFIC ANTIBODIES COMPRISING THE SAME - An anti-HER2 antibody, an anti-c-Met/anti-HER2 bispecific antibody including the same, method for preparing same, and a method of preventing and/or treating a cancer using the same are provided. | 11-12-2015 |
| 20150322165 | ANTI-CMET/ANTI-EGFR/ANTI-HER3 MULTIPECIFIC ANTIBODIES AND USE THEREOF - An anti-EGFR/anti-HER3 antibody or antigen binding fragment thereof, and a method of preventing and/or treating a cancer using the same | 11-12-2015 |
| 20150329642 | MONOCLONAL ANTIBODIES AGAINST C-MET - Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 11-19-2015 |
| 20150343092 | TARGETED GENE DELIVERY TO NON-PHAGOCYTIC MAMMALIAN CELLS VIA BACTERIALLY DERIVED INTACT MINICELLS - A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells. | 12-03-2015 |
| 20150344566 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-13 AND/OR IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 12-03-2015 |
| 20150353647 | Tissue Plasminogen Activator Antibodies and Methods of Use - A molecule that binds specifically to a human tissue plasminogen activator (TPA) or a TPA mutant is provided. The molecule having sub-nanomolar affinity to inhibit fibrin-dependent plasminogen activation with an IC50<5 nM, to inhibit degradation of human fibrin clots without affecting TPA amidolytic activity or non-fibrin-dependent activation, and the amino acid sequence of the TPA mutant is at least 65% identical to SEQ ID NO: 1 or SEQ ID NO: 2. Further provided is a method for treating systemic bleeding and brain hemorrhage after TPA treatment in a patient in need of such treatment. The method comprises administering to said patient an effective amount of the molecule, wherein the molecule selectively inhibits fibrin-augmented plasminogen activation in the patient. | 12-10-2015 |
| 20150368328 | Immunotherapy for Clearing Pathological Tau Conformers - The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject. | 12-24-2015 |
| 20150368329 | Methods of Treating Ocular Diseases - The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating ocular diseases. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit ocular neovascularization. | 12-24-2015 |
| 20150368338 | Interferon Alpha and Omega Antibody Antagonists - The present invention relates to antibodies that broady neutralize interferon-α and interferon-ω, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing. | 12-24-2015 |
| 20150368351 | METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA - An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-κB activation, BAFF-dependent NF-κB activation, and does not alter NF-κB activation without BAFF and APRIL is useful as a therapeutic agent. | 12-24-2015 |
| 20150376283 | FGFR1 AGONISTS AND METHODS OF USE - The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same. | 12-31-2015 |
| 20150376287 | BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA - A bispecific antibody specifically binding to the two targets human CD3ε and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-κB activation, BAFF-dependent NF-κB activation, and does not alter NF-κB activation without BAFF and APRIL is useful as a therapeutic agent. | 12-31-2015 |
| 20160002326 | COMPOSITIONS AND METHODS FOR TREATING RHEUMATOID ARTHRITIS - The treatment of rheumatoid arthritis using engineered multivalent and multispecific binding proteins that target TNF and IL-17 is provided. | 01-07-2016 |
| 20160002333 | Bispecific CD33 and CD3 Binding Proteins - Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33 | 01-07-2016 |
| 20160002357 | BISPECIFIC HETERODIMERIC DIABODIES AND USES THEREOF - Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen. | 01-07-2016 |
| 20160009823 | COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT | 01-14-2016 |
| 20160009824 | TETRAVALENT BISPECIFIC ANTIBODIES | 01-14-2016 |
| 20160017028 | Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component - The present inventors identified inhibition of a combination of EGFR ligands that serve as targets for inhibition of cancer cell proliferation. More specifically, EREG antagonists and TGFα antagonists were found to be useful as inhibitors of cell growth. The present invention relates to pharmaceutical compositions containing EGF family ligand antagonists as components. | 01-21-2016 |
| 20160017038 | Bispecific Molecules That are Immunoreactive with Immune Effector Cells That Express an Activating Receptor and an Antigen Expressed by a Cell Infected by a Virus and Uses Thereof - The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections. | 01-21-2016 |
| 20160017046 | COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC BONE DISORDERS - Provided are compositions comprising one of more molecules that specifically bind to CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2) and methods for treating and improving the symptoms of pathologic bone loss in a subject by administering to the subject a therapeutically effective amount of such compositions. | 01-21-2016 |
| 20160017057 | Single Linker FabFv Antibodies and Methods of Producing Same - The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I): (Vxx) | 01-21-2016 |
| 20160017058 | BISPECIFIC ANTIBODIES AND USES THEREOF - Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response. | 01-21-2016 |
| 20160024185 | IDENTIFICATION OF ANTIBODIES SPECIFIC FOR LYSSAVIRUSES AND METHODS OF THEIR USE - Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses. | 01-28-2016 |
| 20160024199 | HUMAN MONOCLONAL ANTIBODIES THAT BIND INSULIN-LIKE GROWTH FACTOR (IGF) I AND II - Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer. | 01-28-2016 |
| 20160024225 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF - Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins. | 01-28-2016 |
| 20160030559 | BIOMARKER HSP90 FOR PREDICTING EFFECT OF A C-MET INHIBITOR - A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90. | 02-04-2016 |
| 20160031974 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN 0X40 - The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 02-04-2016 |
| 20160032000 | BLOOD-BRAIN-BARRIER DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 02-04-2016 |
| 20160032019 | Antibody constructs for CDH19 and CD3 - The present invention provides to a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct. | 02-04-2016 |
| 20160033518 | BIOMARKER PNCK FOR PREDICTING EFFECT OF A DUAL-TARGETING AGENT - A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene. | 02-04-2016 |
| 20160046715 | T REGULATORY CELLS AND USES THEREOF - The present application relates to generation of regulatory T cells, particularly those generated in the presence of anti-CD80 and anti-CD86 antibodies. The present application also relates to uses of the regulatory T cells in treating subjects undergoing organ transplantation. The present application also relates to uses of the regulatory T cells in treating subjects undergoing tissue grafts. Regulatory T cells may be administered to a subject along with one or more antibodies. | 02-18-2016 |
| 20160046727 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF - Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins | 02-18-2016 |
| 20160046728 | IDENTIFICATION AND MOLECULAR CHARACTERISATION OF PROTEINS, EXPRESSED IN THE IXODES RICINUS SALIVARY GLANDS - The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the | 02-18-2016 |
| 20160046730 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 02-18-2016 |
| 20160051687 | BACTERIALLY-DERIVED, INTACT MINICELLS THAT ENCOMPASS PLASMID-FREE FUNCTIONAL NUCLEIC ACID FOR IN VIVO DELIVERY TO MAMMALIAN CELLS - Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation. | 02-25-2016 |
| 20160053000 | APELIN ANTIGEN-BINDING PROTEINS AND USES THEREOF - This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications. | 02-25-2016 |
| 20160053008 | ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING SAME - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation. | 02-25-2016 |
| 20160053025 | ANTI-C-MET/ANTI-ANG2 BISPECIFIC ANTIBODY - An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody. | 02-25-2016 |
| 20160068591 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND METHODS OF USING THE SAME - Monoclonal antibodies or antigen-binding fragments thereof that bind to | 03-10-2016 |
| 20160068596 | NOTCH PATHWAY INHIBITION - The invention provides Notch pathway inhibition with reduced toxicity. | 03-10-2016 |
| 20160068597 | FDF03 ANTIBODIES AND USES THEREOF - The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer. | 03-10-2016 |
| 20160068605 | CD123 Binding Agents and Uses Thereof - Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein. | 03-10-2016 |
| 20160075753 | MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-eta - Compounds, uses and methods for modulating an immune response are provided. In particular, modulating the interaction of PKCη with CTLA-4 can modulate an immune response. For example, modulating activity or expression of PKCη, and/or modulating activity or expression of CTLA-4, can be used to modulate interaction of PKCη with CTLA-4, thereby modulating an immune response. | 03-17-2016 |
| 20160075777 | ANTI-IL-4/ANTI-IL-13 BISPECIFIC ANTIBODY FORMULATIONS - The present invention provides stable pharmaceutical antibody formulations, including lyophilized formulations, comprising an anti-IL-4/anti-IL-13 bispecific antibody and a buffering system, wherein the pH of the formulation is about pH 7, and wherein the formulation has a low salt concentration in order to reduce the ionic strength of the formulation. The formulations may, optionally, further comprise a non-ionic surfactant, a sugar, and/or a non-ionic stabilizing agent. The formulations can be used in the treatment of various diseases. | 03-17-2016 |
| 20160075785 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 03-17-2016 |
| 20160090427 | POLYPEPTIDE, ANTI-VEGF ANTIBODY, AND ANTI-C-MET/ANTI-VEGF BISPECIFIC ANTIBODIES COMPRISING THE SAME - A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody. | 03-31-2016 |
| 20160095883 | METHOD FOR THE TREATMENT OF OBESITY - The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes. | 04-07-2016 |
| 20160108118 | Anti-TNF-alpha/CXCL10 Double-Targeting Antibody and Use Thereof - The present invention relates to a TNF-α (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-α specific antibody, is a bispecific antibody that effectively binds to both TNF-α and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-α/CXCL10. A composition of the present invention comprises a TNF-α/CXCL-10 double targeting antibody which effectively binds to both TNF-α and CXCL10. The double targeting antibody of the present invention has excellent TNF-α inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-α or CXCL10 single targeting antibody. The composition of the present invention can be used in preventing or treating immunological disease. | 04-21-2016 |
| 20160108130 | RSPO3 Binding Agents and Uses Thereof - The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 04-21-2016 |
| 20160113883 | DELIVERING FUNCTIONAL NUCLEIC ACIDS TO MAMMALIAN CELLS VIA BACTERIALLY-DERIVED, INTACT MINICELLS - Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy. | 04-28-2016 |
| 20160114037 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY - The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))). | 04-28-2016 |
| 20160115221 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY - The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))). | 04-28-2016 |
| 20160115231 | TREATMENT OF MAST CELL RELATED PATHOLOGIES - Methods of inhibiting activation of a mast cell and/or treating a disease induced by activation of a mast cell in a subject are provided. Accordingly there is provided a method comprising contacting a cancerous mast cell with an effective amount of a multivalent agent which binds and activates Siglec-7, thereby inhibiting activation of the cancerous mast cell. Also provided is a method comprising contacting a mast cell with an effective amount of an agent comprising: a first moiety which binds and activates Siglec-7; and a second moiety which binds activates a mast cell activating receptor, thereby inhibiting activation of the mast cell. Also provided are agents and compositions for and methods of inhibiting activation of a mast cell and/or treating a disease induced by activation of a mast cell in a subject. | 04-28-2016 |
| 20160115233 | HIGH FUNCTIONAL BISPECIFIC ANTIBODY | 04-28-2016 |
| 20160115241 | HETERODIMERIC BISPECIFIC ANTIBODIES - Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety. | 04-28-2016 |
| 20160122429 | ANTI-TNF- / ANTI-IL-23 BISPECIFIC ANTIBODIES - Bispecific antibodies are provided that bind Tumor Necrosis Factor alpha (TNFα) and the p19 subunit of Interleukin-23 (IL-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both TNFα and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Axial Spondyloarthropathy, Rheumatoid Arthritis and Psoriatic Arthritis. | 05-05-2016 |
| 20160122435 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 05-05-2016 |
| 20160122438 | MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES - Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided. | 05-05-2016 |
| 20160130347 | Fc-free antibodies comprising two Fab-fragments and methods of use - The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 05-12-2016 |
| 20160131655 | BCMA-BASED STRATIFICATION AND THERAPY FOR MULTIPLE MYELOMA PATIENTS - The present invention relates to methods for the stratification of a multiple myeloma (MM) patient comprising determining whether or not B-cells, preferably malignant B-cells of said patient express BCMA protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (MM) therapy is based on whether or not BCMA is expressed on the cell surface of B-cells, preferably malignant B-cells of a patient. Furthermore, antibody-based therapies for patients who have BCMA positive malignant B-cells are provided. | 05-12-2016 |
| 20160137738 | MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES - Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided. | 05-19-2016 |
| 20160137744 | MET-BINDING AGENTS AND USES THEREOF - The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer. | 05-19-2016 |
| 20160144028 | COMBINATION THERAPY USING DUAL INHIBITOR OF C-MET AND EGFR AND IGF-1R INHIBITOR - A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor | 05-26-2016 |
| 20160145340 | BISPECIFIC-FC MOLECULES - Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules. | 05-26-2016 |
| 20160145354 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 05-26-2016 |
| 20160145355 | BISPECIFIC ANTIBODIES - The present invention provides, inter alia, bispecific antibodies containing a first antigen binding moiety that specifically binds an epitope on human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and a second antigen binding moiety that specifically binds an epitope on a human programmed death 1 (PD-1) receptor. Also provided are pharmaceutical compositions containing such bispecific antibodies, as well as methods and kits for treating cancer using such bispecific antibodies and pharmaceutical compositions. | 05-26-2016 |
| 20160152728 | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII | 06-02-2016 |
| 20160159890 | METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND HUNTINGTON'S DISEASE - This invention relates generally to methods of treatment for neurodegenerative diseases such as Alzheimer's disease, Alzheimer's-related diseases, and Huntington's disease, and more specifically to methods involving the inhibition of the classical pathway of complement activation. | 06-09-2016 |
| 20160159894 | HUMAN FCRN-BINDING MODIFIED ANTIBODIES AND METHODS OF USE - Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation. | 06-09-2016 |
| 20160159908 | Covalent Diabodies and Uses Thereof - The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule. | 06-09-2016 |
| 20160159929 | NOVEL DUAL-TARGETING PROTEIN BINDING SPECIFICALLY TO DLL4 AND VEGF AND USE THEREOF - The present invention relates to a novel dual-targeting protein comprising: a protein that binds specifically to delta-like ligand 4 (DLL4); and an antibody that binds specifically to vascular endothelial cell growth factor (VEGF). | 06-09-2016 |
| 20160159930 | BISPECIFIC ANTIBODIES AND METHODS FOR PRODUCTION THEREOF - The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention. | 06-09-2016 |
| 20160166684 | Treatment of Fibrotic Diseases | 06-16-2016 |
| 20160168242 | ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF | 06-16-2016 |
| 20160168247 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | 06-16-2016 |
| 20160168250 | ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME | 06-16-2016 |
| 20160176959 | STABLE AND SOLUBLE ANTIBODIES | 06-23-2016 |
| 20160176962 | Combination Therapy For Treatment Of Disease | 06-23-2016 |
| 20160176973 | BINDING MOLECULES FOR BCMA AND CD3 | 06-23-2016 |
| 20160176976 | Methods of Manipulating Phagocytosis Mediated by CD47 | 06-23-2016 |
| 20160176978 | Methods of Manipulating Phagocytosis Mediated by CD47 | 06-23-2016 |
| 20160177364 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | 06-23-2016 |
| 20160178644 | METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE | 06-23-2016 |
| 20160185846 | ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS - The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same. | 06-30-2016 |
| 20160185865 | AFFINITY MATURED ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE - The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells. | 06-30-2016 |
| 20160194384 | COMPOSITIONS AND METHODS FOR THE REMOVAL OF BIOFILMS | 07-07-2016 |
| 20160194396 | Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses Thereof | 07-07-2016 |
| 20160194406 | MODULATION OF EFFEROCYTOSIS PATHWAYS FOR TREATMENT OF ATHEROSCLEROTIC DISEASE | 07-07-2016 |
| 20160199487 | MODULATION OF TUMOR IMMUNITY | 07-14-2016 |
| 20160200811 | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation | 07-14-2016 |
| 20160200816 | Methods of Manipulating Phagocytosis Mediated by CD47 | 07-14-2016 |
| 20160200822 | ANTIBODIES WHICH BIND TYPE I CANNABINOID RECEPTOR/ANGIOTENSIS II RECEPTOR HETEROMERS | 07-14-2016 |
| 20160200827 | Bi-Specific Monovalent Diabodies That are Capable of Binding CD123 and CD3, and Uses Thereof | 07-14-2016 |
| 20160251430 | ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES | 09-01-2016 |
| 20160376352 | HUMANIZED ANTI-TAU(pS422) ANTIBODIES AND METHODS OF USE - The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same. | 12-29-2016 |
| 20160376357 | ANTI-C5A ANTIBODIES - The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease. | 12-29-2016 |
| 20160376362 | USE OF AN IL-17/IL-23 BISPECIFIC ANTIBODY FOR TREATING INFLAMMATION - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease. | 12-29-2016 |
| 20160376373 | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 - The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38. | 12-29-2016 |
| 20170233467 | Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular Therapies | 08-17-2017 |
| 20170233472 | ROR1-Binding Molecules, and Methods of Use Thereof | 08-17-2017 |
| 20170233490 | HER3/HER2 BISPECIFIC ANTIBODIES BINDING TO THE BETA-HAIRPIN OF HER3 AND DOMAIN II OF HER2 | 08-17-2017 |
| 20170233491 | DOSAGE AND ADMINISTRATION OF COMBINATION THERAPIES COMPRISING ISTIRATUMAB, USES AND METHODS OF TREATMENT | 08-17-2017 |
| 20170233497 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF | 08-17-2017 |
| 20170233498 | METHODS OF TREATING INFLAMMATION USING IL-17A AND IL-17F CROSS-REACTIVE MONOCLONAL ANTIBODIES | 08-17-2017 |
| 20180022829 | MULTISPECIFIC ANTIGENS BINDING FRAGMENTS AND MULTISPECIFIC ANTIBODIES DERIVED THEREFROM COMPRISING MUTANT CH1 AND CL-KAPPA DOMAINS | 01-25-2018 |
| 20190144542 | ANTI-PD-1 ANTIBODIES AND COMPOSITIONS | 05-16-2019 |
| 20190144549 | ANTI-LAP ANTIBODIES AND USES THEREOF | 05-16-2019 |
| 20190144553 | BI-FUNCTIONAL CHIMERIC PROTEINS AND USES THEREOF | 05-16-2019 |
| 20190144554 | ANTI-DR5 ANTIBODIES AND METHODS OF USE THEREOF | 05-16-2019 |
| 20220135626 | MULTIVALENT PARTICLES COMPOSITIONS AND METHODS OF USE - Provided herein are multivalent particles and compositions of multivalent particles for blocking viral infection. | 05-05-2022 |
| 20220135678 | METHODS AND COMPOSITIONS TO IMPROVE THE SAFETY AND EFFICACY OF CELLULAR THERAPIES - Described herein are novel compositions and methods to improve the safety and efficacy of adoptive cellular therapies of cancer, infection, allergic, degenerative and immune disorders. The disclosure provides a) novel methods and compositions to reduce the accidental insertion of chimeric receptors into cancer cells; b) novel methods to measure the titer of viral vectors; c) novel compositions to generate antigen masking receptors and methods to use such receptors to protect normal cells from immunotherapeutic agents; d) novel compositions and methods to extend the life-span of allogeneic cells, including allogeneic CAR-T cells; e) novel compositions and methods to ameliorate the side-effects of cellular therapies and f) novel compositions of Synthetic Immune Receptors and Ab-TCRs with mutant TCRα constant chains. | 05-05-2022 |
| 20220135686 | ANTIBODY THAT BINDS TO HUMAN PD-L1 - Provided are an antibody that binds to human PD-L1, and a tetravalent bispecific antibody against PD-1 and PD-L1 constructed based on the antibody that binds to human PD-L1. The tetravalent bispecific antibody requires no Fc modification, has no mismatch problems, and the preparation method thereof is simple. The biological activities and physical and chemical properties of the tetravalent bispecific antibody are similar with or even better than those of the monoclonal antibodies. | 05-05-2022 |
| 20220135700 | Bispecific HER2 Ligands for Cancer Therapy - The invention relates to a bispecific HER2-targeting agent that includes (a) a first polypeptide ligand that binds to HER2 extracellular domain 1, (b) a second polypeptide ligand that binds to HER2 extracellular domain 4, and (c) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand. | 05-05-2022 |
